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Abstract 
Glutamine is a very versatile source of energy and a precursor for many molecules 
which are essential to the growth and survival of actively dividing cells. Numerous amino 
acid transporters are involved in the transport and homeostasis of glutamine and ASCT2 is 
one of the most important transporters expressed in mammals, due to its moderate affinity 
for glutamine (Km = 70 - 90 µM), its ubiquitous organ expression, and its correlation with 
aggressive forms of cancer. Yet, the regulation of ASCT2 in a non-pathological setting is 
poorly understood. In this study, I developed a new cell model for the study of ASCT2 by 
examining the molecular and functional characteristics of glutamine uptake in RWPE-1, an 
immortalized prostate epithelial human cell line.  
The expression of the canonical isoform of ASCT2 (SLC1A5) mRNA in RWPE-1 
cells was confirmed by quantitative PCR and ASCT2 protein by western blotting. 
Immunofluorescence microscopy confirmed ASCT2 to be abundant and primarily localized 
to the plasma membrane. Radio-labelled glutamine uptake in RWPE-1 cells determined that 
ASCT2 is the major contributor (45 %) of glutamine transport in this cell line. Additionally, 
I have confirmed that EGF regulates the glutamine uptake via ASCT2, by regulating, through 
an unknown mechanism, the trafficking of the transporter to the plasma membrane.  
Thus, I conclude that the RWPE-1 cell-line is the first model to date used to study 
the detailed assessment of amino acid transporters’ role in the physiology of the prostate; 
moreover, RWPE-1 is a physiologically relevant model for the study of ASCT2 regulation. 
Moreover, I performed a largescale MYTH screening to target ASCT2 and discover potential 
interactors of the transporter which may help my future studies to further investigate and 
understand the regulation of the transporter.   
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Chapter 1 : Introduction 
 
Glutamine, a Very Essential “Non-Essential” Amino Acid 
Most cells are able to produce glutamine (Figure 1.1) via the reaction catalyzed by the enzyme 
glutamine synthetase (GS) and for this reason, it has been classified as a “non-essential” amino 
acid; nevertheless, glutamine (gln) is one of the most abundant amino acids in the plasma (0.6 - 
0.9 mmol/L) (Labow and Souba, 2000).  
 
 
 
Figure 1.1. Chemical structure of the amino acid L- glutamine.  Adapted from public domain 
image (https://en.wikipedia.org/wiki/Glutamine#/media/File:L-Glutamin_-_L-Glutamine.svg).  
Regardless of its classification, glutamine has extensive cellular and physiological 
functions in mammalian cells which are summarized in Figure 1.2; particularly, these functions 
are related to the growth and survival of actively dividing cells such as enterocytes, fibroblasts, 
and lymphocytes (Brand, 1985, Ko et al., 1993, Engström and Zetterberg, 1984).  
Glutamine, enters the mitochondria via an unknown glutamine transporter, this is still a 
widely debated topic in the scientific community. The only available information was provided by 
the isolation of rat’s kidney mitochondria and the extraction of an uncharacterized 24kDa 
glutamine transporter (Indiveri et al., 1998). Possible candidates for glutamine transport in the 
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mitochondrion are thought to be the orphan transporters from the subfamilies SLC25A25, 39, and 
16  (Palmieri, 2008).  
However the mechanism of entry, glutamine is a major source of non-toxic ammonia which 
is utilized in the urea cycle, transamination reactions, gluconeogenesis, and production of energy 
in the form of ATP (Labow et al., 2001). Glutamine is also utilized as a metabolic intermediate 
that contributes carbon and nitrogen for the synthesis of other amino acids, fatty acids, nucleic 
acids, and proteins (Neu et al., 1996). Moreover, glutamine is the major source of cellular 
glutamate, and it can be the limiting step in the synthesis rate of glutathione, an antioxidant that 
protects cells from oxidative stress (Matés et al., 2002, Roth et al., 2002). Glutamine also 
coordinates protein translation, metabolic flux, and nitrogen balance to maintain tissue 
homeostasis and cell volume control (Dall'Asta et al., 1990). In addition to contributing to 
anaerobic respiration in cancer, glutamine play a fundamental role the maintenance of the 
metabolic needs of rapidly proliferating cells such as activated lymphocytes and stem cells 
(Newsholme et al., 1985).  
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Figure 1.2. Biosynthetic fate and metabolism of glutamine (Altman et al., 2016)  
 
Over the last 20 years it has been recognized that the demand for glutamine exhibited 
during certain conditions has exceeded the cellular endogenous production capacity of this amino 
acid, so much so that in this context, glutamine has been reclassified as “conditionally essential” 
(Souba, 1993). In fact, cells typically derive energy via aerobic metabolism in which they 
metabolize glucose to pyruvate (glycolysis) which is then converted into energy (ATP and NADH) 
in the mitochondria by oxidative phosphorylation. Under anaerobic conditions, the same cells will 
reduce pyruvate into lactate instead and they will synthesize the necessary glutamine via nitrate 
reduction of glutamate which requires ATP (Baggetto, 1992). Somatic cells, due to genetic 
aberrations in key tumour suppressor genes such as p53 and/or to dysregulation of onco-related 
proteins such as PI3K, Akt, myc and Ras, undergo tumorigenic transformation resulting in 
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metabolism becoming anaerobic to support their greater need of glycolytic intermediates and 
glutamine for macromolecular synthesis and redox maintenance (Medina et al., 1992, Bode, 2001, 
Cairns et al., 2011). This gives them a major advantage, despite the low efficiency of their catabolic 
metabolism, for they are able to either bypass or disrupt all the check points responsible for 
metabolic homeostasis and growth regulation. Having glutamine metabolism provides a source of 
carbon utilized as an oxidative source of energy for the generation of ATP and other biosynthetic 
precursors (Vander Heiden et al., 2011). This metabolic change is universally recognised as the 
phenotype of tumours or Warburg Effect (Cantor and Sabatini, 2012).  
Given the metabolic and regulatory versatility of amino acids and particularly of glutamine, 
it is not a surprise that it has been reported as the main oxidizable substrate for actively dividing 
cells (Ohh, 2012, Reitzer et al., 1979). De novo synthesis of glutamine is not sufficient to meet the 
increased demand in tumour cells. This results in an increase in the expression of transporters such 
as LAT1 (Macheda et al., 2005) and ASCT2 (Fuchs and Bode, 2005), which are responsible for 
the exchange/uptake of glutamine and other amino acids. Interestingly, ASCT2 alone may play a 
key role in cell transformation by modulating amino acid uptake, most importantly glutamine, 
which is important for metabolic reprogramming by enabling cancer cells to survive and proliferate 
under hypoxia (Metallo et al., 2012). 
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Transporters for The Amino Acid Glutamine 
Amino acid homeostasis is a highly-regulated mechanism driven by many transporters and of 
particular interest are transport systems with specificity for glutamine, since these transporters 
have pivotal roles in cell growth, proliferation, and viability in both normal and abnormal cells 
(Bode, 2001, McGivan and Bungard, 2007, Pochini et al., 2014). Unlike glucose, glutamine can 
be transported across the plasma membrane, with different affinities and mechanisms, by 
numerous amino acid transporters (Hensley et al., 2013, Kanai and Endou, 2001, Kanai and 
Hediger, 2004, Scalise et al., 2016).  
The mammalian amino acid transporters known to be involved in the maintenance of 
glutamine homeostasis are denoted in Table 1.1, on the basis of their transport mechanism, by 
systems A (SLC38A1 and SLC38A2) and N (SLC38A3, SLC38A5, and SLC38A7), system L 
(SLC7A5, SLC7A8) and by the transporters B0AT1 (SLC6A19), ATB0+ (SLC6A19), and ASCT2 
(SLC1A5) (Kanai and Hediger, 2004, Pochini et al., 2014, Bode, 2001, Kanai and Hediger, 2003, 
McGivan and Bungard, 2007, Utsunomiya-Tate et al., 1996).  
Table 1.1. Amino acid transporters involved in glutamine homeostasis in mammals.  
Member Alias Variant Transport mechanism Km for Gln  
SLC1A5 ASCT2 NP_005619.1 Na+ - gln/ aa0 antiport  0.07-0.09 mM 
SLC6A14 ATB0+ NP_009162.1 2Na+ - 1Cl− /gln co-transport 0.6 mM 
SLC6A19 B0AT1 NP_001003841 .1 Na+ - gln co-transport 0.25 mM 
System L  
SLC7A5 LAT1 NP_003477 .4 Gln/ large aa0 antiport  0.5 mM 
SLCA8 LAT2 NP_036376.2 Gln/ small aa0 antiport  0.3-0.9 mM 
System A  
SLC38A1 SNAT1 NP_001265317 .1 Na+ - gln cotransport  498 mM 
SLC38A2 SNAT2 NP_061849.2 Na+ - gln cotransport  1.5 mM 
System N  
SLC38A3 SNAT3 NP_006832.1 Na+ - gln/H+ antiport  0.7 -1 mM 
SLC38A5 SNAT5 NP_277053.2 Na+ - gln/H+ antiport  0.7 -1 mM 
SLC38A7 SNAT7 NP_060701 .1 Na+ - gln/H+ antiport  0.7 -1 mM 
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Systems A and System N (SLC38 or SNATs) are sodium-dependent facilitative transporters which 
co-transport amino acids (glutamine, methionine, proline, serine, asparagine, glycine, and 
histidine) inwardly by following the sodium electrochemical gradient (Mackenzie and Erickson, 
2004, Hägglund et al., 2011, Schiöth et al., 2013, Bröer, 2014); they are set apart on the basis of 
their ability to be inhibited by the amino acid analogue metil-amino isobutyric acid (MeAIB) 
(Christensen et al., 1965). SNATs are expressed broadly in the body, including the intestine and 
prostate (Schiöth et al., 2013, Jenstad and Chaudhry, 2013, Kondou et al., 2013). 
System L members LAT1 (SLC7A5) and LAT2 (SLC7A8) are widely expressed in kidney, 
placenta, brain, prostate, and other tissues; their transport is usually sodium-independent and may 
only occur when in a heteromeric state with their co-expressed heavy chain unit 4F2hc (del Amo 
et al., 2008). Their substrate specificity is very broad and includes tryptophan, phenylalanine, 
serine, leucine, histidine, alanine, glycine, and at low affinity, glutamine and threonine (Kanai et 
al., 1998, Pineda et al., 1999, Fraga et al., 2005, Yoon et al., 2005, Fotiadis et al., 2013). 
Transporter B0AT1 (SLC6A19) is a sodium-dependent electrogenic glutamine transporter 
expressed in the intestine, skin, stomach, liver, and prostate (Kleta et al., 2004, Seow et al., 2004, 
Böhmer et al., 2005, Bröer and Palacín, 2011, Bröer, 2014). The transporter recognizes a wide 
range of substrates which includes leucine, cysteine, and glutamine; however, arginine, aspartate, 
glutamate, lysine, and the inhibitor MeAIB are not recognised (Bröer et al., 2004, Camargo et al., 
2005). 
Transporter ATB0+ (SLC6A14) is considered a wide spectrum amino acid transporter for 
its broad substrate selection which includes small and large neutral amino acids such as leucine 
and glutamine, cationic amino acids, and even carnitine (Bode, 2001, Nakanishi and Tamai, 2011, 
Hatanaka et al., 2001). Human ATB0+ is expressed principally in colon, lung, eye and mammary 
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gland and it is inhibited by α-methyl-DL-tryptophan (α-MT) and Arginine (Sloan and Mager, 
1999, Ganapathy and Ganapathy, 2005).  
A brief overview of these transporters characteristics and other related transporters 
involved the homeostasis of glutamine, will enlighten the complexity and the challenges in 
elucidating the homeostasis of amino acids in mammalian tissues (Figure 1.3). 
 
 
Figure 1.3. Network of transporters involved in glutamine homeostasis  (Pochini et al., 
2014)  
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Alanine Serine Cysteine Transporter 2 (ASCT2)  
The transporter ASCT2 (SLC1A5) is encoded by the gene NC_000019.10 annotated on 
chromosome 19q13.32; ASCT2 localization among mammalian tissues is broad and includes 
kidney, intestine, brain, lungs, placenta, pancreas, and prostate (Kekuda et al., 1996, Utsunomiya-
Tate et al., 1996, Bröer et al., 1999, Bröer and Brookes, 2001, Deitmer et al., 2003, Gliddon et al., 
2009, Kanai and Hediger, 2004, Namikawa et al., 2014). Although three different splice variants 
have been reported, only the variant NP_005619.1 has been characterized and is known to consist 
of 2873 nucleotides and 8 exons, producing a functional peptide of 541 amino acids (Kekuda et 
al., 1996, Kanai et al., 2013).  
Two dimensional models of hASCT2 topology suggests that the transporter structure may 
be similar to the glutamate transporter 1 (GLT-1) (Jiang and Amara, 2011, Reyes et al., 2009, 
Slotboom et al., 1999) and consist of 10 transmembrane domains (TMD) and alternating intra and 
extra cellular loops. The C- and N-termini of the transporter are predicted to extend intracellularly 
(Figure 1.4). Important features of the transporter include two N-glycosylation sites, namely N163 
and N212, which are located on the predicted large extracellular loop between TMD3 and TMD4. 
These two glycosylation sites were recently correlated with the ability of the transporter to reach 
the plasma membrane when transiently overexpressed in HEK-293 cells (Console et al., 2015). 
Although both N-glycolic moieties are important for the correct translocation of the transporter 
from the ER to the PM, the N212 glycolic moiety seems to be crucial for the correct placement of 
the transporter within the bi-layer. Notably, glycosylation-deficient hASCT2 is not affected 
functionally when reconstituted into proteoliposomes nor when transiently expressed in HEK-293 
cells (Console et al., 2015), which suggests that the N-glycans are not correlated with the 
transporter functionality, but rather with its trafficking as previously described for other 
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transporters such as SLC26A3, intestinal ion exchanger and OCTN1, a carnitine transporter 
(Hayashi and Yamashita, 2012).  
 
 
Figure 1.4. hASCT2 putative topology.  Adapted from Jiang and Amara, 2011. The large loop 
between the 7th and 8th TMD, the two hairpins denoted with “I and II” (blue), the linker region 
(yellow), and the COOH-terminus are hypothesized to be involved in the transportation of the 
substrate. The two N-glycosylation sites, N163 and N212, are represented by the orange balls. 
  
(Adapted from Jiang & Amara, 2010)
1 2 3 4 5 6 7 8
I
II
NH2 COOH
Linker
Int
Ext
N163 
N212 
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The three-dimensional structure of hASCT2 is unknown. However, some structural 
predictions were obtained by performing homology modeling on the known crystal structure 
(1XFH) of the archaeal glutamate transporter (Gltph) from Pyrococcus horikoshii (Yernool et al., 
2004), which suggest that the functional ASCT2 may be an oligomer (Figure 1.5). Furthermore, 
data obtained using cross-linking techniques support this hypothesis and provide evidence that the 
human ASCT2 transporter forms at least homodimers (Scalise et al., 2014). Moreover, the 
hypothesis of a functional oligomeric hASCT2 is further supported by the recent unveiling of the 
trimeric crystal structures of the human excitatory amino acid transporter 1 (EAAT1), also a 
member of the SLC1 family (Canul-Tec et al., 2017). 
 
Figure 1.5. Putative hASCT2 three-dimensional structure.  Monomeric (A) and oligomeric (B) 
hASCT2 structures generated with SWISS MODEL and readapted with SWISS-PDB viewer. The 
ribbon model was based on P. horikoshii (Gltph) crystal structure (1XFH) (Kanai and Hediger, 
2004).   
A B
Ext
Int
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The integral membrane protein ASCT2 (AlaSerCys transporter 2) despite its name, is a 
predominant sodium dependent, neutral amino acid exchanger in mammalian cells with a moderate 
preference for glutamine (Km= 70– 90 µM) and high preference for glutamine (Km= 39 µM) in the 
proteo-liposome (Utsunomiya-Tate et al., 1996, Torres-Zamorano et al., 1998, Bode, 2001, Bröer 
et al., 1999, Pingitore et al., 2013, Pochini et al., 2014, Scalise et al., 2014, Zander et al., 2013, 
Avissar et al., 2008, Oppedisano et al., 2007). ASCT2 is widely expressed in numerous tissues 
where it is responsible for glutamine delivery (Christensen et al., 1967, Christensen, 1990, 
Pingitore et al., 2013, Pochini et al., 2014, Scalise et al., 2014, Torres-Zamorano et al., 1998, 
Zander et al., 2013).  
Studies on the functional characteristics of the murine and more recently, human isoforms 
of ASCT2 have all confirmed that the transporter catalyzes an obligatory antiport of other neutral 
amino acids with glutamine, and that the ability of ASCT2 to transport its substrate is strictly 
dependent on the presence of extracellular sodium (Na+) which can’t be substituted with other ions 
such as K+ and or Li+ (Bröer and Palacín, 2011, Torres-Zamorano et al., 1998). 
The exact stoichiometry of the transport is still unknown, although some kinetic data 
obtained by studying the purified human isoform of ASCT2 into proteoliposomes suggested a 1:1 
sodium to amino acid coupling ratio (Pingitore et al., 2013, Scalise et al., 2014). 
Aspects of the electrical net ion flux of transport are yet to be clarified. Some studies have 
shown that the Na+ transported inwardly should induce electrical currents therefore generating an 
electrogenic transport (Kekuda et al., 1996, Pingitore et al., 2013, Torres-Zamorano et al., 1998, 
Grewer and Grabsch, 2004). Other studies, however, describe the net ion flux of the ASCT2-
dependent transport to be zero, defining the transport as electroneutral (Bröer et al., 1999, 
Utsunomiya-Tate et al., 1996). A study focused on ASCT2-dependent transport cycle suggested 
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the possibility that more than one Na+ ion may be transported along with the translocation of the 
amino acids across the plasma membrane. Therefore, even if the amino acid exchange is thought 
to be electroneutral, because of the movement of Na+ ions across membrane, the overall transport 
cycle is definitely electrogenic (Zander et al., 2013). 
Recent studies of the kinetics of the hASCT2 reconstituted into proteoliposomes, have 
established that the influx of glutamine is sodium coupled (1:1 ratio) in exchange for an 
intracellular neutral amino acid such as Gln, Ser, Asp, or Thr. Instead, the intracellular sodium 
seems to bind to the protein allosterically, regulating its activity without being transported (Scalise 
et al. 2014).  
Because the crystal structure of ASCT2 is not known, studies on the pharmacology of the 
transporter has been challenging; therefore, potential inhibitors of ASCT2 were designed on the 
basis of the structural homology of ASCT2 with the glutamate transporter Gltph (Grewer and 
Grabsch, 2004, Esslinger et al., 2005, Albers et al., 2012). For example, the competitive inhibitor 
serine biphenyl-4-carboxylate (BenSer), which is structurally similar to an inhibitor of the 
glutamate transporter, blocks ASCT2 with moderate affinity (Ki= 30 μM) (Albers et al., 2012). 
Other studies have identified compounds designed on a (N/L) -γ-substituted glutamine, the most 
specific being L-γ-glutamil-ρ-nitroanilide (GPNA), characterizing a compound that inhibits with 
a low affinity (Ki= 250 μM) at 100 μM glutamine (Esslinger et al., 2005). These inhibitors were 
successfully used in studies targeting the ASCT2-dependent transport pharmacologically and 
arrest the development of cell proliferation (Polet et al., 2016, Wang et al., 2014, Wang et al., 
2015). 
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ASCT2 and Pathology  
ASCT2 is physiologically relevant in many tissues. For example, in the placenta, ASCT2 mediates 
the transport of glutamine used in the fetal liver to synthesize glutamate, an essential amino acid 
for the correct function of the fetus metabolism (Torres-Zamorano et al., 1998). In the brain under 
ischemic conditions ASCT2 has a protective action by facilitating the efflux of glutamine from 
astrocytes in exchange for the protonated glutamate (glt+) released in the synaptic cleft, thereby 
reducing the toxic activity of this neurotransmitter (Bröer et al., 1999, Gegelashvili et al., 2006). 
ASCT2 is also used as an anchoring “receptor” by human retroviruses allowing them to infect 
human cells (Antony et al., 2011, Marin et al., 2003). 
Over the last decade, the expression and function of ASCT2 has been increasingly 
correlated with angiogenesis, which marked it as a potential target for antitumor drug treatment 
(Fuchs et al., 2004, Fuchs et al., 2007, Kaira et al., 2015, Shimizu et al., 2014, Nicklin et al., 2009, 
Bode et al., 1995, Bode, 2001). The shift toward anaerobic metabolism undertaken by cells during 
tumorigenesis, to meet the sudden need for glutamine to support the generation of ATP is very 
well known as the “Warburg effect” (Vander Heiden et al., 2009, Liberti and Locasale, 2016a, 
Liberti and Locasale, 2016b). This metabolic shift causes an increased presence of membrane 
transporters involved in glutamine uptake (Cantor and Sabatini, 2012, Ohh, 2012). Among these, 
ASCT2 is one of the most highly represented glutamine transporters in tumours, which suggests 
that this transporter may play an important role in the maintenance of the cancer phenotype by 
modulating glutamine uptake in this context (Fuchs et al., 2007, Kanai and Hediger, 2004, Palmada 
et al., 2005, Wang et al., 2014, Metallo et al., 2012). In fact, microarray studies on both non-
malignant and malignant prostate tissues have shown a correlation between hASCT2 expression 
and a more aggressive behaviour of adenocarcinoma (Li et al., 2003).  
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A role for ASCT2 in angiogenesis is supported by the described cooperative mechanism 
of regulation between ASCT2 and the large neutral amino acid transporter-1 (LAT1), another 
major player involved in this process (Nicklin et al., 2009, Shimizu et al., 2014, Bothwell and 
Bode, 2017). Active LAT1, forming a heterodimer complex with 4F2 heavy chain (4F2hc), is a 
Na+-independent antiporter which exchanges intracellular glutamine for extracellular essential 
amino acids such as arginine, phenylalanine, tyrosine, tryptophan, and most importantly leucine 
(Fuchs and Bode, 2005, Uchino et al., 2002). Data suggest that ASCT2 utilizes the amino acids 
transported by LAT1 to transport glutamine back into the system both for energy purposes and to 
fuel LAT1 transport cycle. The alleged cooperation between ASCT2 and LAT1 should provide 
the necessary leucine for the regulation of mTOR, a key regulator of the cells also involved in 
uncontrolled cell proliferation (Fuchs and Bode, 2005, Fuchs et al., 2007, Nicklin et al., 2009, 
Ganapathy et al., 2009).  
The concept of ASCT2 being involved in the regulatory system of mTOR was introduced 
by studies in hepatoma cells, where silencing ASCT2 using RNA interference (RNAi) triggers a 
reduction in the activity of mTOR leading to cell apoptosis within 48 h (Fuchs et al., 2004, Fuchs 
et al., 2007), although the underlying mechanisms are unclear. Another report proposed a possible 
regulation of the transporter via EGF stimulated pathways involving mTOR, MAPK, PI3K, and 
Rho, though conducted without separating the ASCT2-dependent transport from the 
B0AT1/B0AT2-dependent transport (Avissar et al., 2008). A similar regulation, involving EGF 
and the kinases SGK1, SGK3, and PKC which are activated by mTORC2, was reported in Xenopus 
laevis oocytes (Palmada et al., 2005) although the ASCT2 transporter does not harbor the 
canonical consensus sequences for these kinases. Nevertheless, studies on ASCT2 expression in 
cancer tissues have shown a regulation by tumour suppressor pRb via the transcription factor E2F-
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3 which is also involved in the regulation of other amino acid transporters (Reynolds et al., 2014). 
These data reinforce the relevance of ASCT2 in this context and highlighting the possible role of 
mTOR in the regulation of the transporter.  
16 
 
ASCT2 and its Regulators 
To understand the regulation of ASCT2, it is important to have knowledge of possible interactions 
occurring between the transporters and other proteins. Unfortunately, very few studies have been 
aimed at understanding the interactome of ASCT2. Very little information is available regarding 
the interaction and co-regulation of ASCT2 by and/or with other proteins. Among the few 
examples that have been described is a physical interaction between ASCT2 and the epidermal 
growth factor receptor (EGFR) (Lu et al., 2016). The complex formation between ASCT2 and 
EGFR, was exploited as a pharmacological target with the anticancer agent cetuximab in the 
treatment of tumours overexpressing EGFR (Lu et al., 2016). A similar study conducted in 
astrocytes, described an interaction between the serotonin transporter (SERT) and ASCT2 which 
leads to a downregulation of SERT’s activity and a reduction of the functions mediated by the 
serotonergic system (Seyer et al., 2016).  
Another interaction which seemed to open a new door toward a further understanding of 
ASCT2 molecular regulatory mechanism was the description of the physical interaction between 
hASCT2 and the scaffold protein, PDZK1 (Scalise et al., 2014). PDZK1 interacts with many other 
proteins forming complexes, thereby coordinating the interplay of multiple proteins at the cell 
membrane in response to growth factors such as EGF, in breast cancer (Kim et al., 2013, Hu et al., 
2009). More examples of the regulatory nature of PDZK1 toward membrane transporters can be 
found in studies focused on the regulation of several members of the SLCs family such as OCTN1 
(Kato et al., 2005), OCTN2 and PEPT1 (Sugiura et al., 2008) which results in change of transport 
activity rate and regulated recycling and/or trafficking (Kim et al., 2013, Walther et al., 2015). 
PDZK1’s expression is limited to epithelial cells and it is overexpressed in a variety of carcinomas 
where they interact with MAP17, a membrane-associated protein involved in regulation of cell 
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proliferation (Ghosh et al., 2000, Kocher et al., 1998). Despite these findings, most of my 
understanding of the regulation of hASCT2 is either incomplete or unknown. For these reasons, a 
deeper insight into the basic biology of hASCT2 will fill an essential gap in the field relating to 
the mechanisms implicated in promoting and supporting angiogenesis. The identification of the 
key regulatory pathways that control hASCT2 activity may allow for the development of inhibitors 
which could be used as a valuable target for anticancer agents (Nakanishi and Tamai, 2011). 
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EGFR and EGF, Roles in Cellular Regulation  
ASCT2 provides amino acids which are essential in cellular processes regulated by growth factors 
(Turner and Grose, 2010, Avraham and Yarden, 2011). Crucial for correct cellular functions is the 
Epidermal Growth Factor (EGF) which exerts its effects by binding to its membrane receptor 
EGFR (or ErbB1), therefore activating the intracellular signalling pathways controlling cell 
growth, proliferation, differentiation, migration, adhesion, and apoptosis (Yarden and Pines, 2012, 
Wong, 2003, Jorissen et al., 2003, Ko et al., 1993, Sibilia et al., 1998, Wolfgang et al., 2003). An 
overview of the EGF-dependent signalling cascades is depicted in Figure 1.6. 
 
 
Figure 1.6. EGF-dependent signalling network  (Kolch and Pitt, 2010).  
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Immediately after binding with its ligand, EGFR undergoes dimerization, this causes the 
activation of the kinase domains and the trans-autophosphorylation of intracellular tyrosine 
residues (Honegger et al., 1989, Ferguson, 2008). At the same time, the EGF/EGFR complex is 
internalized very quickly via clathrin-mediated endocytosis which triggers a downregulation of the 
signalling cascade (Rappoport and Simon, 2009). The internalized receptor is separated from its 
ligand and de-phosphorylated by cellular phosphatases; then the EGFR is either recycled to the 
plasma membrane or sent to lysosome for degradation (Avraham and Yarden, 2011). These 
phosphorylation events induce the activation of many downstream cascades, starting with the 
formation and activation of the Shc-Grb2-Sos complex and its recruitment to the plasma membrane 
(Rozakis-Adcock et al., 1992, Simon and Schreiber, 1995) which in turn recruits the downstream 
effectors of Ras (Raf) to the plasma membrane, and initiates a series of phosphorylation events 
which starts the Ras/MAPK/Erk 1/2 signalling cascade (Kyriakis, 2009, Sakaguchi et al., 1998). 
This signalling cascade has many targets: (1) the activation of Ras/MAPK promotes the beginning 
of the cell cycle and cell proliferation (Avraham and Yarden, 2011) and stimulates cell migration 
(Jorissen et al., 2003); (2) MAPK/Erk 1/2 can translocate to the nucleus and phosphorylate several 
transcription factors, therefore altering gene expression (McCubrey et al., 2007); (3) Active Ras 
interacts with RalGEF, promoting the conversion of GDP to GTP and activation of RhoGTPases 
such as Cdc42, leading to cytoskeletal rearrangements and cell migration (Cantor et al., 1995, 
Jullien-Flores et al., 1995); (4) Activated Ras also targets the phospholipase C (PLCγ/ε) which 
hydrolyzes the phosphatidylinosidol 4,5- biphosphate (PIP2) to diacylglycerol (DAG) and inositol 
1,4,5-triphosphate (IP3). This reaction activates the protein kinase C (PKC) which induces the 
release of actin-modifying proteins from the plasma membrane, which will act as a second 
messengers thus regulating (a) the reorganization of actin cytoskeleton and cell migration (Chen 
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et al., 1996), and (b) the regulation of intracellular calcium release (Rhee, 2001, Kelly and Levin, 
2001).  
Another major signalling cascade initiated by the activation of the EGFR is the PI3K/Akt 
pathway. Upon EGFR activation, PI3K is recruited to the plasma membrane where it binds and 
phosphorylates second messenger phosphatidylinositol 3,4-biphosphate (PIP2) to 
phosphatidylinositol 3,4,5-triphosphate (PIP3), which in turn recruits the phosphoinositide-
dependent kinase 1 (PDK1) and the serine-threonine kinase Akt (Kyriakis, 2009, Chalhoub et al., 
2009). The activation of the PI3K/Akt pathway is a key regulator of cellular functions, including 
the promotion of antiapoptotic responses, the starting of the cell cycle, and cell survival (Jorissen 
et al., 2003). For example, activation of Akt leads to: (1) the phosphorylation and inhibition of 
BAD, a member of the Bcl-2 family of pro-apoptotic factors (Datta et al., 1997); (2) the 
phosphorylation and activation of κB inhibitor (IkB) which in turns activates the nuclear factor κ-
light-chain-enhancer of B cells (NFκB), therefore increasing the transcription of anti-apoptotic 
genes (Bai et al., 2009); (3) the promotion of protein synthesis via activation of mammalian target 
of rapamycin (mTOR) through the inhibition of the tuberous sclerosis proteins (TSC1 and TSC2) 
GTPase activity and activation of Rheb (Courtney et al., 2010). 
Due to its pivotal role in cell physiology, alteration in EGF signalling may be a key 
contributor to uncontrolled cell proliferation. Overexpression, deletion and mutation of the EGFR 
gene have been correlated with different types of cancer (Turner and Grose, 2010, Avraham and 
Yarden, 2011, Burgess, 2008, Casanova et al., 2002, Klos et al., 2006, Salomon et al., 1995, 
Rajkumar and Greipp, 2001). For example, mutations occurring within the EGFR gene are known 
to contribute to a ligand-independent activation of the receptor with a strong enough signal to cause 
a constant activation of the downstream signalling cascade but insufficient to target the EGF 
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receptor for the natural post-activation degradation (Avraham and Yarden, 2011, Normanno et al., 
2006, Lemmon and Schlessinger, 2010). Studies on oral, lung, and prostate cancer, have reported 
a correlation between the earlier development of these tumours and the overexpression of EGFR, 
caused by an increase in both gene amplifications and transcription (Grandis and Sok, 2004). Most 
importantly, increased EGF receptor levels have been associated with shorter survival and 
increased presence of metastasis (Veale et al., 1993, Radinsky et al., 1995).  
Therefore, due to the significant role of EGF and EGFR during development and its 
correlation with neoplastic transformation which also involves downstream kinases such as mTOR 
(Nomura et al., 2003, Dibble and Cantley, 2015), its involvement in regulating nutrient 
transporters associated with tumour development and survival has been subject of many studies 
(Aggarwal et al., 2011, Ray et al., 2005, Tsuchihashi et al., 2016, Zelenaia et al., 2000).  
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mTOR Signalling 
Mechanistic target of rapamycin (mTOR) (Figure 1.7) is a widely conserved serine/threonine 
kinase which integrates and regulates many signals of cell growth including growth factors, stress, 
and nutrients including amino acids (Wullschleger et al., 2006, Foster and Fingar, 2010, Nobukuni 
et al., 2005).  
 
Figure 1.7. mTOR signalling pathway  (Fantus et al., 2016). 
 
Mammalian TOR exists in two structurally different large complexes (mTOR complex 1 
and mTOR complex 2) which share some interrelated functions within the cell: mTORC1 is 
exclusively associated with the regulatory-associated protein of TOR (RAPTOR) and the proline-
rich Akt substrate 40 kDa (PRAS40) (Avruch et al., 2009b, Hara et al., 1998, Hara and Mizushima, 
2006, Kim et al., 2011, Thedieck et al., 2007, Vander Haar et al., 2007, Wang et al., 2007, Sancak 
et al., 2007, Sancak et al., 2010); whereas, mTORC2 is exclusively associated with rapamycin-
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insensitive associated protein of TOR (RICTOR), mammalian stress-activated map kinase-
interacting protein 1 (mSin1) and rictor-associated proteins (protor 1/2) (Frias et al., 2006, Jacinto 
et al., 2004, Jacinto et al., 2006, Pearce et al., 2007, Pearce et al., 2011, Sarbassov et al., 2004). 
Both complexes share the catalytic mTOR subunit (TOR), the mammalian lethal with SEC thirteen 
8 (mLST8 or GbL), DEP domain containing TOR-interacting protein (DEPTOR), and the 
Tti1/Tel2 complex (Jacinto et al., 2004, Kaizuka et al., 2010, Kim et al., 2002, Kim et al., 2003, 
Peterson et al., 2009).  
mTORC1 has many functional roles, one of which is to regulate cell growth by 
phosphorylating the 70 kDa ribosomal protein S6 kinase (S6K1), which in turn regulates the 
eukaryotic initiation factor 3 (eIF3) translation complex (Holtz et al., 2005, Ma et al., 2008). Also, 
mTORC1 increases mRNAs translation by hyper-phosphorylating the eukaryotic translation 
initiation factor 4E (eIF4E) binding protein (4E-BP1), therefore causing it to release the eIF4E 
(Gingras et al., 2004). 
 mTORC1 is also considered a signal integrator for amino acid availability which leads to 
protein turnover and autophagy, but the origin of the signal and the exact mechanism via which 
mTOR senses intracellular amino acids is still ambiguous (Avruch et al., 2009a, Durán et al., 2012, 
Heublein et al., 2010, Jewell et al., 2013, Jewell and Guan, 2013, Kim et al., 2011, Wullschleger 
et al., 2006, Yu et al., 2010, van der Vos and Coffer, 2012). Some theories suggest that intracellular 
amino acid sensors are working together with transporters such as ASCT2 and LAT1 to support 
the regulation of the sensing mechanism exerted by mTOR (Kim, 2009). Other data suggest that 
some amino acid transporters, such as PAT1, are translocated from the plasma membrane to the 
lysosome/endosome where they aid the modulation of mTOR activity in response to a growth-
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dependent stimulus by importing amino acids from the extracellular environment into the cell 
(Sagné et al., 2001).  
mTORC2 is a newly discovered complex and very little is known about its function; 
nevertheless, its primary role appears to include the regulation of cytoskeletal remodeling and cell 
migration by phosphorylating many kinases such as PKA, PKG, and PKC (Jacinto et al., 2004, 
Sarbassov et al., 2004, Gan et al., 2012, Thomanetz et al., 2013, Li et al., 2014) and the modulation 
of the trafficking of some nutrient transporters (Hara et al., 2002, Kim et al., 2002, Edinger, 2007). 
However, the most important role of mTORC2 is to modulate cell survival, proliferation, and 
growth by phosphorylating and activating the Akt Ser/Thr kinase at serine 473 and promoting 
Rheb GTP-loading; however, the underlying mechanism of regulation of mTORC2 is yet to be 
clarified (Guertin and Sabatini, 2007, Jacinto et al., 2004, Sarbassov et al., 2004, Sarbassov et al., 
2006, Wullschleger et al., 2006). Finally, mTORC2 activity has been also correlated with the 
regulation of ion transport via the phosphorylation of the SGK1 kinase (García-Martínez and 
Alessi, 2008). 
Many studies over the last decade support the important role of mTOR signalling pathways 
in pathogenesis. Some mutagenic events such as loss of p53 and dysregulation of the PI3K 
signalling pathway promote constitutive mTORC1 activation (Averous and Proud, 2006, Feng et 
al., 2005, Fingar et al., 2004). The exact mechanism and contribution to oncogenesis caused by 
the dysregulation of the protein synthesis machinery downstream of mTORC1, is unclear 
(Dowling et al., 2010, Hsieh et al., 2010, Yang and Guan, 2007). 
mTORC2 has been also associated with cancer proliferation, mainly due to its regulation 
of Akt phosphorylation. In many gliomas, the overexpression of mTORC2 has been reported to 
further promote the constitutive assembly and activation of mTORC2 leading to an increase in 
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further cell proliferation and invasion potential (Hietakangas and Cohen, 2008, Masri et al., 2007). 
The loss of the tumour suppressor PTEN is a crucial event in the development of prostate cancer 
in mice, caused by a dysfunction of the mTORC2 activity (Guertin et al., 2009). These data support 
the important role of mTORC1 and mTORC2 in promoting the development of cancer and suggest 
that designing of effective pharmacological agent aimed at reducing the activity of either complex 
is essential for successful anticancer therapies. To date, however, there is no pharmacological 
agent selective enough to target and inhibit mTORC2 without also affecting mTORC1, therefore 
the prospects of a short-term solution are small. 
  
26 
 
Objectives of the Study  
To date, our basic understanding of the biochemistry of ASCT2 is not sufficient to allow us to 
make use of this transporter as a target for drug therapy. Furthermore, questions remain 
unanswered on the fundamentals of ASCT2 regulation and the identity of its interactors. Because 
of the broad distribution, activity, and major role in cell metabolism, a deeper understanding of 
hASCT2 is crucial. Moreover, even the limited information I have was primarily obtained in 
models which are not representative of a normal tissue, such as immortalized cell lines derived 
from primary tumours such as HEPG2, Caco-2 and BeWo cells, or embryonic cell lines such as 
HEK-293 or oocytes derived from Xenopus laevis. Therefore, the overall objective of my research 
is to develop better tools to gain a holistic understanding of the basic cell biology of hASCT2 and 
its regulatory mechanisms, primarily in the context of cellular transformation. In addition, the aim 
was to develop and characterize an appropriate cellular model for the study of hASCT2 and 
confirm the EGF-dependent regulation of hASCT2 in an appropriate model which is representative 
of a normal tissue such as RWPE-1 cells. Finally, I will identify mechanisms involved in EGF-
dependent regulation of ASCT2. Taken together these data will fill essential gaps in our 
understanding of the underlying regulatory mechanisms of endogenous human isoform of ASCT2.  
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Chapter 2 : The regulation of ASCT2-dependent glutamine uptake 
and its distribution at the PM are modulated by EGF  
 
Introduction 
Homeostasis in mammalian cells is a highly complex process which is regulated by many 
pathways including uptake and metabolism of amino acids. Of particular interest are transport 
systems with specificity for glutamine since these transporters have pivotal roles in cell growth, 
proliferation and viability in both normal and abnormal cells (Bode, 2001, Pochini et al., 2014, 
McGivan and Bungard, 2007). Glutamine has a major role in cellular proliferation and unlike 
glucose, it may be transported with different affinities and mechanisms by diverse, non-
homologous amino acid transporters (Bungard and McGivan, 2004, Kanai and Endou, 2001, 
Hensley et al., 2013). The mammalian amino acid transporters known to be involved in the 
maintenance of glutamine homeostasis are denoted, on the basis of their transport mechanism, by 
systems A, N and, L and by transporters B0AT1, ATB0+, and ASCT2 (Christensen et al., 1967, 
Christensen, 1990, McGivan and Bungard, 2007, Pochini et al., 2014).  
The integral membrane protein ASCT2 is expressed ubiquitously in numerous mammalian 
tissues and is a sodium dependent neutral amino acid exchanger with a moderate preference for 
glutamine (Km= 70 – 90 µM) in cell systems (Bröer et al., 1999, Pingitore et al., 2013, Pochini et 
al., 2014, Scalise et al., 2014, Torres-Zamorano et al., 1998, Utsunomiya-Tate et al., 1996, Zander 
et al., 2013). Over the last decade, it has been increasingly apparent that the expression and 
function of ASCT2 correlates with angiogenesis in many tissues which marked it as a potential 
target for antitumor drug treatment (Albers et al., 2012, Fuchs and Bode, 2005, Fuchs et al., 2007, 
Kaira et al., 2015, Nicklin et al., 2009, Shimizu et al., 2014, Namikawa et al., 2014). Together, 
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these data highlight the important role of ASCT2 in both physiological and pathophysiological 
settings. Therefore, a more in depth understanding of the regulatory mechanisms of the 
endogenous human isoform of ASCT2, in a model which is representative of a non-tumorigenic 
tissue, will facilitate targeted approaches to be used in those clinical settings where uncontrolled 
cellular proliferation needs to be halted. Nevertheless, the majority of what is currently known 
about ASCT2 structure and function has been obtained by heterologous expression of the protein 
and subsequent analysis in transformed cell lines, in Xenopus laevis oocytes or by reconstitution 
of the transporter into proteoliposomes (Console et al., 2015, Fuchs et al., 2007, Palmada et al., 
2005, Shimizu et al., 2014). Currently, there is no well-established, fully characterized cellular 
model for the study of ASCT2 and its regulation. Thus, to address this gap, I have characterized 
the human epithelial prostate cell line, RWPE-1 (Bello et al., 1997, Webber et al., 2001). RWPE-
1 cells are non-tumorigenic (in nude mice), which have been immortalized with HPV18 allowing 
them to mimic both the physiological morphology and androgen response of the tissue of origin. 
Indeed, RWPE-1 cells express the functional markers of the prostate tissue such as PSA and AR, 
the markers identifying their epithelial origin such as CK18 and CK18, and the tumour suppressor 
markers such as the p53 gene and the Rb protein (Bello-DeOcampo et al., 2001a, Webber et al., 
1997). Furthermore, RWPE-1 cells have been adopted as a negative control in many studies 
investigating features indicative of tumorigenesis such as increased cell mobility, invasiveness, 
and metastasis (Aggarwal et al., 2011, Fernández-Martínez et al., 2010, Giannoni et al., 2009). 
Based on these properties, I characterized RWPE-1 cells to be used as a physiologically relevant 
model to have a better understanding of the basic biology and of the regulatory mechanisms of the 
endogenous human glutamine transporter, ASCT2. The effects on glutamine uptake induced by 
EGF have been previously reported (Iannoli et al., 1997, Ray et al., 2003, Ray et al., 2005). Some 
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studies investigating the regulation of ASCT2 have suggested that the transporter’s activity may 
be EGF-induced (Avissar et al., 2008, Palmada et al., 2005, Rosario et al., 2013). Therefore, I 
have investigated the effects of EGF on the regulation of the transporter in RWPE-1 cells.  
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Materials and Methods 
 
Materials 
Keratinocyte serum free medium (K-SFM- 17005042), Dulbecco’s modified Eagle’s medium 
(DMEM), bovine pituitary extract (BPE), fetal bovine serum (FBS), supplemental epidermal 
growth factor (EGF), Hank’s balanced salt solution (HBSS), and PureLinkTM RNA Mini isolation 
kit were purchased from Life Technologies (Burlington, ON). The SuperScript® III RT kit, 
Superscript First-Strand Synthesis System for RT-PCR, fluorescently labelled antibodies, plasma 
membrane and nuclear dyes were purchased from Invitrogen (Carlsbad, CA). Quantitative PCR 
reactions were performed with the EvaGreen 2X qPCR MasterMix-ROX from ABM inc. 
(Richmond, BC) using StepOne Plus thermo-cycler by Applied Biosystems (Burlington, ON). 
Goat HRP-conjugated anti-rabbit antibodies were purchased from BioRad (Mississauga, ON). The 
chemiluminescent substrate for immunoblot analysis was purchased from Mandel Scientific 
(Guelph, ON). Labelled glutamine ([3H]-glutamine) was purchased from Moravek Biochemicals 
(Brea, CA). The cellular grade EGF, amino acids, and EGFR inhibitor (tyrphostin AG1478) used 
in this study were purchased from Sigma Aldrich (Oakville, ON). Antibodies against tyrosine 
phosphorylated protein (4G10 Platinum-#05-1050), pan EGFR (#06-847), and hASCT2 
(#ABN73) were purchased from Millipore (Billerica, MA). The hASCT2.rbd-antibody-conjugated 
was purchased from Metafora Biosystems (Evry cedex, France). Antibodies against β-actin 
(#4967) and hASCT2 (#5345) were purchased from Cell Signalling Technologies (Danvers, MA). 
The cocktails of protease and phosphatase inhibitors (cat#11836153001) were purchased from 
Roche Diagnostics (Mississauga, ON). All other chemicals were purchased from BioShop 
(Burlington, ON) unless otherwise specified.  
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ASCT2.RBD 
ASCT2 is utilized by human retroviruses as an anchoring “receptor” to infect the host (Antony et 
al., 2011, Marin et al., 2003). This characteristic was exploited by Metafora Biosystems (Evry 
cedex, France) in designing an anti-ASCT2 retroviral binding domain (RBD) that could bind 
specifically to the protein residing at the plasma membrane. The ligand is constituted of an 
undisclosed isolated viral glycoprotein fused to a fragment antigen binding (Fab) of a rabbit grown 
antibody where the a fluorescently labelled secondary antibody will bind to. 
Cell Line Choice Rationale 
Human epithelial prostate cells (RWPE-1) were chosen based on hASCT2 expression pattern data 
obtained from the European Bioinformatics Institute (http://www.ebi.ac.uk/). Furthermore, these 
cell lines are derived from primary human tissues and they are physiologically relevant for my 
studies in that they are reported as non-tumorigenic in mice (Bello et al., 1997, Webber et al., 
2001). RWPE-1 cells are immortalized with human papilloma virus 18 (HPV18) DNA containing 
the adenoviral SV40 large T antigen gene, and the adenoviral E1a and E7 protein genes. This 
genetic combination allows the modulation of pRb and p53 proteins levels instead of their 
inactivation. This allows RWPE-1 cells to retain all the characteristics of the tissue of origin such 
as prostate specific antigen (PSA) and androgen receptor (AR) expression, growth factor and 
androgen response, expression of cytokeratin 18 and 8, and expression of p53. Moreover, an 
extensive knowledge on the morphology and tissue-specific response of metabolic pathways 
stimulated by growth factors in RWPE-1 cells is available and it could be involved in the regulation 
of hASCT2 (Reynolds and Kyprianou, 2006, Giannoni et al., 2009). Furthermore, the presence of 
characterized sister cell lines derived by RWPE-1 with different grades of neoplasticity (RWPE-2 
and RWPE-3 cells) may be the ultimate tool in studying the regulation of hASCT2 at different 
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stages of the disease in comparable models (Bello et al., 1997, Bello-DeOcampo et al., 2001a, 
Bello-DeOcampo et al., 2001b). RWPE-1 cells represent a clinically relevant model since the 
Canadian Cancer Society reported that ¼ of the total deaths of male cancer patients are due to 
prostate cancer and that previous data correlate hASCT2 expression with a more aggressive 
prostate adenocarcinoma (Li et al., 2003). 
Human liver cells (THLE-3) (Pfeifer et al., 1993) were chosen as negative control, due to 
the data obtained from the European Bioinformatics Institute, reporting very low mRNA 
expression of ASCT2 in the liver. However, I confirmed that these cells do express abundant 
amount of functional hASCT2, therefore are no longer suitable as a negative control for my studies.  
Human embryonic kidney cells (HEK-293), were chosen as a positive control for technical 
assays as they are a very well characterized model which has been used in previous studies 
investigating ASCT2 (Scalise et al., 2014, Zander et al., 2013). 
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Cell Culture 
Immortalized human prostate epithelial RWPE-1 cells were purchased from ATCC (CRL-11609) 
and cultured per ATCC’s guidelines. RWPE-1 monolayers are kept in proliferative conditions in 
Keratinocyte SEM (Gibco) serum free medium supplemented with 0.05 mg/mL of bovine pituitary 
extract and 5ng/mL of human recombinant epidermal growth factor at a temperature of 37ºC in a 
humidified incubator and a 5% (v/v) CO2 atmosphere. HEK-293 were purchased from ATCC and 
were cultured in DMEM supplemented with 10% (v/v) FBS at a temperature of 37 ºC in a 
humidified incubator and a 5% (v/v) CO2 atmosphere. Transformed human liver epithelial THLE-
3 cells, purchased from ATCC, were chosen as a low/no expressing tissue for (SLC1A5) ASCT2 
and tested as potential negative control to be used in parallel for my studies. THLE-3 cells were 
purchased from ATCC and were kept in proliferative conditions on pre-coated plates in BEGM 
basal medium supplemented with 5 ng/mL EGF, 70 ng/mL phosphoethanolamine, and 10% (v/v) 
FBS at a temperature of 37ºC in a humidified incubator and a 5% (v/v) CO2 atmosphere.  
EGF Treatments 
RWPE-1 cells were cultured as previously described, incubated in sodium uptake buffer (5hr, 37 
°C) and exposed to extracellular EGF (300 ng/mL, 3, 5, and 10 min, 37 °C) in the presence or 
absence of EGFR inhibitor, Tyrphostin AG1478 (20, 40, and 60 µM, 10 min, 37 °C). Cells were 
then lysed, and protein analysis obtained via immunoblotting. RWPE-1 and HEK-293 cells were 
cultured as described above, treated with extracellular EGF (300 ng/mL, 30 min, 37 °C) and used 
for the study of ASCT2’s mRNA expression and ASCT2 protein analysis via Immunoblot. RWPE-
1 cells cultured as described above and exposed to extracellular EGF (300 ng/mL, 3 min, 37°C) 
were used to study both ASCT2’s functionality via transport assays and ASCT2’s cellular 
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distribution via surface protein biotinylation assays, immunofluorescence, and in-plate flow 
cytometry.  
RNA Extraction and cDNA Synthesis 
RWPE-1 and HEK-293 monolayers (90% confluence) were washed twice with PBS (4°C) and 
total RNA was isolated using the PureLinkTM RNA mini kit as per manufacturer’s instruction. 
Briefly, lysis buffer supplemented with 1% (v/v) mercaptoethanol was added to the cells and they 
were scraped off the plate. The suspension was then homogenised by syringing (10 times) using a 
26-Gauge needle. Total RNA (~400 ng/µl yield) was obtained via column elution in RNAse free 
water and stored at -80 °C. Purity, integrity and concentration of the extracted RNA were verified 
with Agilent 2100 Bioanalyzer (Santa Clara, CA). Total RNA which met quality criteria was 
converted to cDNA using SuperScript® III RT kit as per manufacturer’s instructions. Briefly, first 
strand cDNA was synthesized using the Superscript First-Strand Synthesis System for RT-PCR. 
For each sample in a volume of 10 µl, total RNA (1µg), 1 µl (10mM) dNTPs Mix, 1 µl (50 µM) 
Oligo20 (dTs), and DEPC water were combined and heated to 65 °C for 5 min then chilled on ice 
for 1 min. A second mixture containing 2 µl (10mM) DTT, 2 µl 10X RT buffer, 4 µl (25 mM) 
MgCl2, 1µl (40 units/µl) RNAse OUT recombinant RNAse inhibitor and 1 µl (200 units/µl) of 
SuperScript III enzyme was added to each sample except the negative control, followed by 
incubation at 50 °C for 50 min, then 85 °C for 5 min. The tubes were chilled on ice for 5 min 
before the addition of 1 µl of E. coli RNase H (2 units/ µl) and incubation at 37 °C for 20 min. The 
cDNA was stored at -20 °C. 
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Quantitative PCR 
Detection and quantification of hASCT2 (SLC1A5) expression levels in RWPE-1 cells was 
performed via qPCR using the EvaGreen 2X qPCR MasterMix-ROX in a total volume of 20 µl 
(10 µl EvaGreen Master Mix, 1 µg of cDNA and a final concentration of 250 nM of each of 5’ and 
3’ primers). Gene specific primers sequences for hASCT2 including the reference genes GAPDH, 
HPRT1 and HMBS are reported in Table 2.1. The reaction was performed with a standard thermal 
profile, followed by melting curve analysis to ensure the amplification of a single and unique 
product per reaction. Briefly, the reaction was conducted in three steps: (1) enzyme activation: 1 
cycle of 10 min at 95 °C; (2) denaturing, annealing and extension: 15 sec at 60 °C, 40 cycles of 1 
min at 95 °C; (3) melting curve: 15 sec at 95 °C, 1 min at 60 °C, 15 sec at 95 °C and 15 sec at 60 
°C. All samples were run in technical triplicate and each experiment included a no-template 
negative control (NTC). Each experiment was repeated at least 3 times. To verify the amplification 
efficiency, standard curves for the cDNA target and each set of primers were established; qPCR 
assays were performed on total cDNA from RWPE-1 cells. Relative gene expression between 
hASCT2 and the reference genes was calculated using the geometric averaging of multiple internal 
control genes method and by comparing it to the data obtained from HEK-293 cells 
(Vandesompele et al., 2002).  
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Table 2.1. Primers used in this study for qPCR.  hASCT2 (SLC1A5) primers were designed 
using the Clone Manager 9 software and they were analyzed again via the IDT- Oligo design and 
analysis tool. The remaining primers sequences were provided by Dr. Pamela Plant (Li Ka Shing 
Knowledge Institute).  
 
Gene 
Primer sequences 5’-3’ 
Slope 
*Eff= 
10^ 
(1/slope) Forward Reverse 
hASCT2 
(NP_005619.1) 
AGCTGCTTATCCGCTTCTTCAA AGCAGGCAGCACAGAATGTA -3.39 1.97 
GAPDH 
(NM_002046) 
CAATGACCCCTTCATTGACC GACAAGCTTCCCGTTCTCAG -3.48 1.93 
HPRT1 
(NM_000194) 
CCTGGCGTCGTGATTAGTGAT AGACGTTCAGTCCTGTCCATAA -3.33 1.99 
HMBS 
(BC019323.1) 
TGCAACGGCGGAAGAAAA AGCTGGCTCTTGCGGGTAC -3.37 1.98 
* Efficiency of the primers as defined by (Pfaffl, 2001). 
 
Protein Extraction and Western Blot Analysis 
THLE-3 and RWPE-1 cells monolayers were cultured as described above and were washed twice 
with PBS (4°C) and protein extraction was performed using 1 % (v/v) NP-40 lysis buffer. Total 
cell lysates were incubated on ice for 5 min, subjected to syringing with a 26-Gauge needle to 
solubilize the plasma membrane and then centrifuged (19000 g, 5 min, 4 °C). Protein quantification 
of the supernatant was done using Bio-Rad PC DC Protein Assay kit based on modified Lowry 
assay. The absorbance was read at 750 nm and the concentration of the samples was calculated 
using a standard curve made of increasing concentrations of BSA. Total cell lysate (10 or 20 µg) 
was resolved by 12 % (w/v) SDS-PAGE (Bio Rad Mini-PROTEAN Tetra System) (90 min, 150 
V) and the protein was transferred on transfer buffer-activated nitrocellulose membrane (Bio-Rad 
– 1620090 - 0.45 microns) using a Bio-Rad semi-dry apparatus (60 min, 20 V).  
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The membranes were blocked (5% (w/v) milk/ TBST, 1 h, 25 °C) and incubated overnight at 4 °C 
with antibodies against hASCT2 (1:1000, 1% (w/v) milk/TBST), antibodies against tyrosine 
phosphorylated protein (1:2000) or β-actin (1:2000) (4 °C, 1 % (w/v) milk/TBST). Total lysate of 
EGF-treated HeLa cells (Millipore 20-168) was used as a positive control. The following day, 
membranes were washed 3 times for 10 min each in TBST, then incubated with goat-anti-rabbit 
horseradish peroxide conjugated secondary antibodies (1:3000, 1% (w/v) milk/ TBST, 1 h, 25 °C). 
The membrane was then washed (3 times for 10 min each in TBST) and incubated in 
chemiluminescent substrate solution for 1 minute, exposed to an X-ray film and developed.  
Densitometry and Normalization 
Densitometry of the bands detected via Immunoblot was obtained using Image J. The 
Normalization was obtained using either β-actin or for phosphorylated kinases, their equivalent 
pan. Relative normalizing value was obtained by dividing all the normalizing controls values (NC) 
by the highest NC density value. The data was normalized by subtracting the densities of my 
protein of interest (PI) and that of the relative normalizing control (rNC) in their respective lanes. 
The untreated control is set at 1 and all treatments are calculated accordingly.  
In-situ Protein Biotinylation Assays and Immunoblot 
RWPE-1 cells were grown to 90% confluence as described above, treated in the presence or 
absence of EGF (300 ng/mL, 3 min, 37 °C) and immediately moved to an iced-water bath to stop 
trafficking. All the biotinylation steps were performed at 4 °C unless indicated otherwise. Cells 
were then washed 3 times with PBS and incubated for 1 h with 2 mL of Sulfo-NHS-SS-Biotin (1 
mg/mL, in PBS; Pierce, Rockford, Illinois). Cells were rinsed three times with PBS containing 100 
mM glycine followed by a 15 min quenching step followed by three quick washes in PBS. RWPE-
1 cells were scraped in 300 µL of NP-40 lysis buffer, and let lyse for 10 min on ice. Lysates were 
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syringed 10 times with a 26-Gauge needle and centrifuged at 19000 g for 5 min at 4 °C. Equal 
concentrations of lysate were incubated with 30µL of streptavidin-conjugated beads per sample 
(15 h at 4°C). After rinsing beads three times with NP-40 buffer, protein was eluted at 90°C for 10 
min in standard 1X protein loading buffer without DTT (to minimize IgG contamination). Protein 
was resolved on a 12% (w/v) SDS-PAGE for 90 min at 15 V. The nitrocellulose membrane 
obtained after semi-dry transfer was blocked with 5% milk and probed with antibodies against 
hASCT2 (Millipore, 1:1000), phosphorylated EGFR (1:2000), and pan-EGFR (1:2000) in 1 % 
(w/v) milk/TBST at for 15 h followed by probing with secondary HRP-conjugated antibodies 
(1:4000, 1 % (w/v) milk/TBST, 25°C, 1 h). Protein signals were detected via enhanced 
chemiluminescence (ECL) solution, developed on film and analyzed by densitometry using 
ImageJ software.  
Total [3H]-glutamine Uptake Assays 
To measure the kinetics of glutamine transport in RWPE-1 cells, radio-labelled glutamine uptake 
was measured. RWPE-1 cells were grown in Keratinocyte SFM medium (GIBCO) in 5 % CO2 at 
37 °C and plated at ~1.2 x 106 cells/well in 6-wells plates or at ~0.5 x 104 cells/well in a 24-wells 
plate and allowed to adhere for 24 h. Cells were rinsed twice with sodium (Na+) uptake buffer. 
Transport assays were performed at 37 °C. The transport was started by adding 50 µM of [3H]-
glutamine (2 μCi/mL, 25 °C) and stopped at the indicated times by washing with x sodium-free 
buffer (4°C). The cells were lysed (2 N NaOH, 1 h, 25 °C) and protein concentration was 
determined with a modified protein Lowry Assay (BioRad; Mississauga, ON). [3H]-glutamine 
uptake was measured by standard liquid scintillation counting. Transport is expressed as picomoles 
of substrate per mg of protein (pmols/mg).  
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Specific [3H]-glutamine Uptake Assays 
To identify only the ASCT2-dependent glutamine transport, distinguish between different amino 
acid transport systems and assess the sodium-dependent/independent glutamine transport 
mechanisms in RWPE-1, cells were treated for 15 min at 37°C in the presence or absence of 2 mM 
competitive amino acids inhibitors (threonine to inhibit specifically hASCT2, histidine to inhibit 
system N, arginine to inhibit ATB0+, phenylalanine to inhibit B0AT1, and MeAIB to inhibit 
System A). In this context, the uptake of radio-labelled glutamine (50 µM [3H]-glutamine, 2 
µCi/mL) was measured in RWPE-1 monolayers via the modified cluster-tray method (Gazzola et 
al., 1981). Cells were plated at ~5 x 104 cells/well in 24-wells culture plates and allowed to adhere 
for 24 h. Cells were rinsed twice with either sodium (Na+) or choline (Ch+) uptake buffer. Transport 
assays were performed at 37 °C in the presence or absence of sodium via the Gazzola’s modified 
cluster-tray method (Gazzola et al. 1981) using buffer containing [3H]-glutamine (50 µM, 2 
μCi/mL) and in the presence or absence of competitive amino acids and inhibitor. The transport 
was stopped at 3 min by washing the cells sodium-free buffer (4°C). The cells were lysed in 2 N 
NaOH, protein concentration was determined with a modified protein Lowry Assay and [3H]-
glutamine uptake was measured by standard liquid scintillation counting. Following transport 
assays, cells were lysed (4 °C, 1 h, shaking) with 2 N NaOH. Protein concentrations of cell lysates 
were determined with a modified protein Lowry Assay (BioRad; Mississauga, ON) and [3H]-
glutamine uptake was measured by standard liquid scintillation counting. Transport is expressed 
as picomoles of substrate per mg of protein (pmols/mg) at 3 min.  Na+-independent glutamine 
uptake was defined in presence of choline chloride. The Na+-dependent glutamine uptake was 
calculated by subtracting the transport in presence of choline chloride from the total transport 
uptake in the presence of sodium. Each transporter contribution was obtained by subtracting the 
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residual uptake after the inhibition of each transporter from the Na+-dependent uptake (systems A, 
N and transporters ASCT2, B0AT1 and ATB0+) and from the choline uptake (system L only).  
Immunofluorescence Microscopy of Endogenous hASCT2 
RWPE-1 cells were grown as to 65 % confluence on microscopy cover slips (1.5 µm thickness- 
Carl Zeiss) as described above and then transferred in serum-free media for 15h. Cells at 70 % 
confluence were kept in sodium buffer (5 h, 37 °C). All further steps were performed at 25°C 
unless otherwise specified. Cells were rinsed 3 times with warm (37 °C) HBSS, exposed to EGF 
(300 ng/mL, 37 °C, 3 min), and fixed (2 % (v/v) PFA (in HBSS) for 20 min) immediately after 
treatment. Successively, RWPE-1 cells were incubated in 50 mM NH4Cl in PBS for 10 min, to 
reduce auto fluorescence and washed once with 95 mM glycine and 3 times with PBS. Cells were 
treated with 10 % (w/v) BSA for 1h to block non-specific antibody binding and probed with anti-
hASCT2.rbd (1:100, Metafora Biosystems, 3 % (w/v) BSA/PBS, 30 min, 37 °C). Cells were 
washed, probed with donkey anti-rabbit IgG (H+L) antibody AlexaFluor555 (1:2000, 3 % (w/v) 
BSA/PBS, 1 h, 37 °C) and the membrane was stained with Alexa488- conjugated WGA (1:3000 
PBS). Cells were then washed 3 times with PBS, permeabilized for 5 min with 0.1 % (v/v) TritonX-
100 in PBS (supplemented with 3 % (w/v) BSA), and treated with 10 % (w/v) BSA for 1h. Cells 
were then, re-probed with anti-hASCT2.rbd and secondary antibodies Alexa555 as described 
above. Nuclei were stained with DAPI (1:30000) and the cells were mounted on microscopy slides 
(0.5 mm thickness – Carl Zeiss) with DAKO mounting media and left to dry in the dark 15h. 
In-plate Flow cytometry 
RWPE-1 cells were cultured as a monolayer to 65 % confluence in 12-well plate (Costar 
#DWG00674) as described above and then in serum-free basal media for 15 h. Cells at 70 % 
confluence were kept in sodium buffer (5 h, 37 °C), rinsed 3 times with warm (37 °C) HBSS, 
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exposed to EGF (300 ng/mL, 37 °C, 3 min) and fixed in 2 % (v/v) PFA (in HBSS) for 20 min 
immediately after treatment. To reduce auto fluorescence, cells were incubated in 50mM NH4Cl 
in PBS for 10 min. Cells were blocked with 10 % (w/v) BSA for 30 min and probed with 
hASCT2.RBD (1:50-metafora Biosystems, 3 % (w/v) BSA/PBS, 1 h, 37 °C). Cells were washed, 
probed with donkey anti-mouse IgG (H+L) antibody AlexaFluor594 (1:2000, 3 % (w/v) BSA/PBS, 
1 h, 37 °C), and the nuclei were stained with DAPI (1:30000) to allow cell localization with 
ImageXpress microscope. After probing and staining, the cells were kept in 1mL of PBS and 
scanned with the ImageExpress flow cytometer. Analysis of the surface fluorescence emitted by 
labelled hASCT2 was performed using Acuity Meta express 6. 
The software, detects the fluorescence emitted by labelled ASCT2 to identify the 
boundaries of the plasma membrane, this will provide a value of the fluorescence emitted by all 
the positively probed cells present in the well and automatically removing the background if any, 
before and after the treatment. The data obtained is similar to that obtained with a flow cytometer, 
with the difference that the cells are not being detached from the plate. Five independent 
experiments were conducted. 
Statistical analysis  
Data are reported as mean ± SEM, unless otherwise specified. Statistical analysis on the data was 
performed by paired two tailed t-test with Graph Pad Prism 6 statistical software package. 
Differences were considered significant at P <0.05 and P<0.001 with a confidence interval of 99% 
(as indicated). Each value represents the mean of at least triplicate experiments with measures at 
least 6 replicate measurements per condition, unless otherwise indicated. 
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Results 
 
Analysis of THLE-3 Cells Revealed Presence of Endogenous ASCT2. 
After performing a bioinformatic analysis on the expression of ASCT2 in various tissues, THLE-
3 cells were chosen as a possible negative control. However, I confirmed that THLE-3 cells express 
ASCT2 protein abundantly (Figure 2.1a). The visualization of ASCT2 protein appears to be 
different than that previously described in the literature (Console et al., 2015, Marin et al., 2003). 
Indeed, a smear located between 57 and 75k Da was detected which could represent different 
stages of glycosylated ASCT2 transporter. Also, a defined band visible at 150 kDa may suggest 
formation of ASCT2 complexes which were not resolved by the denaturing conditions.  
ASCT2-dependent [3H]-glutamine uptake in the presence of sodium is responsible for 
about 55 % of the total glutamine uptake (Figure 2.1b).  
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Figure 2.1. THLE-3 cells express hASCT2. (A) Detection of hASCT2 protein detection in 
THLE-3 cells. THLE-3 cells were grown and extracted proteins were resolved by SDS-PAGE as 
described in Materials and Methods. Proteins were analyzed via immunoblot using antibodies 
against ASCT2. A smear (**) is visible between 57 and 75 kDa, representing endogenous 
non/glycosylated hASCT2 respectively and a single band (*) visible at 150 kDa represents putative 
hASCT2 oligomers. Representative immunoblot of 3 independent experiments. (B) ASCT2 is 
responsible for 55 % of the total sodium-dependent glutamine uptake in THLE-3. THLE-3 
cells were grown and treated as described in Materials and Methods. The transport was performed 
in the presence of sodium buffer containing [3H]-glutamine plus or minus 20 µM Nimesulide, 
2mM Arginine, Histidine, and Phenylalanine. Data presented as mean ± SEM (N=3 independent 
experiments).  
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Endogenous hASCT2 Expression and Localization Patterns in RWPE-1 Cells.  
I confirmed RWPE-1 as a model for the study of endogenous hASCT2 by using validated primers 
and qPCR. The canonical isoform of ASCT2 is encoded by the gene SLC1A5 and is endogenously 
expressed in RWPE-1 cells (Figure 2.2a). ASCT2 mRNA expression is significantly less abundant 
than that observed in HEK-293 cells when measured against the same endogenous reference genes 
(HPRT1, HMBS, and GAPDH). Previous studies (Marin et al., 2003) and more recently by 
Console and colleagues (2015), have shown that ASCT2 undergoes N-glycosylation. My data 
confirm that ASCT2 is present in RWPE-1 cells and can be identified with apparent molecular 
mass of 75 and 57 kDa which are likely to represent the monomeric glycosylated and non-
glycosylated forms of ASCT2 respectively (Figure 2.2b). In addition, a third band at 150kDa is 
present suggesting the presence of a putative complex (which can occur during these types of 
analysis with membrane proteins, due to their highly hydrophobic nature, despite the presence of 
denaturing conditions). Although the glycosylation of ASCT2 was not confirmed experimentally 
via PGNase enzymatic reaction, the distribution of putative glycosylated forms and complexes of 
ASCT2 I have examined in RWPE-1 cells, is consistent with data previously shown in HEK-293 
(Pingitore at al., 2013; Scalise et al., 2014).  
Having confirmed the presence of ASCT2 mRNA and protein in RWPE-1 cells I performed 
immunofluorescence assays to determine the endogenous distribution of ASCT2 in these cells 
using two different antibodies. Using the Metafora Biosystems-produced ASCT2.rbd-conjugated 
antibody, I observed that ASCT2 protein is distributed, as expected, at the plasma membrane 
(Figure 2.3); however, ASCT2 seems to be distributed more abundantly and in a punctate manner, 
in the cytoplasm just adjacent the plasma membrane and around the ER area (Figure 2.3). 
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Figure 2.2. hASCT2 is expressed in RWPE-1 cells.  (A) Relative mRNA expression of 
hASCT2 in RWPE-1 compared to HEK-293 cells. RWPE-1 cells were grown in Keratinocyte 
SFM medium (GIBCO) in 5 % CO2 at 37 °C at 0.5 x 10
6 cells/60 mm dish. RNA extracted from 
HEK-293 cells was used as a control. Data are presented as the mean ± SEM (N=4 HEK-293 cells 
and N=6 RWPE-1 cells). (B) hASCT2 protein detection in RWPE-1 cells. RWPE-1 total cell 
lysate was analysed via immunoblotting using two different antibodies against ASCT2 (Cell 
Signalling (c) and Millipore (m). Two specific bands can be seen with both antibodies, presumably 
representing endogenous glycosylated (**) and non-glycosylated (*) hASCT2 at 75 and 57 kDa 
respectively. A band at 150 kDa (***) representing putative hASCT2 oligomers was also detected. 
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Figure 2.3. Cellular distribution of endogenous hASCT2 in RWPE-1. RWPE-1 cells were 
grown, fixed, and permealized as described in Materials and Methods. Cells were probed with 
hASCT2.RBD (Metafora Biosystems) and with secondary antibodies Alexa Fluor® 555 donkey 
anti-mouse IgG. ASCT2 (red) is distributed in clusters at the plasma membrane, some protein 
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seems to reside just underneath the bilayer (yellow arrow), while the remaining the protein is 
spread within the cytoplasm in a punctate manner. Nuclei (blue) were stained with DAPI. Cell 
membranes (green) were stained with WGA-Alexa488. Scale bar – 10 µm. Images are 
representative of 3 independent experiments. Images (1 and 2) are a Z stack (24 slices) collected 
at 0.28 µm intervals with a Zeiss laser scanning confocal fluorescent microscope-64X. Controls - 
RWPE-1 cells labelled with secondary antibodies only (A) and WGA only (B) are shown. Scale 
bar – 5 µm.  
  
48 
 
Endogenous hASCT2 is Fully Functional and Represents the Primary Contributor of 
Glutamine Transport in RWPE-1 Cells.  
The nature of the glutamine transport in RWPE-1 cells was investigated and the optimal transport 
time was determined to be within the 3 to 5 min’ range, which is well within the linear phase of 
uptake (Figure 2.4a). Subsequently, functional studies in RWPE-1 were performed to investigate 
the contribution of ASCT2 to the overall uptake of glutamine in these cells. I performed transport 
assays which selected each individual transporter and/or system (where individual transporters 
could not be differentiated) and used a combination of specific amino acids and pharmacological 
compounds based on their known inhibition of each targeted transporter. I established that, as 
predicted, the major contributor (45 %) to sodium dependent glutamine uptake in RWPE-1 is 
hASCT2 (Figure 2.4b). The remaining uptake is due to transporters: B0AT1 (18 %), ATB0+ (7 %) 
and transporter system N (13 %). Sodium independent uptake (14 %) is due almost exclusively to 
system L transporters. I did not detect any transport from system A transporters.  
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Figure 2.4. Glutamine transport in RWPE-1.  (A) Time course of [3H]-glutamine uptake in 
RWPE-1. Data are presented as mean ± SD (each data point represents six replicates). (B) ASCT2 
is the major contributor of [3H]-glutamine uptake in RWPE-1 cells. Cells were pre-treated (30 
min, 37 °C) in the presence or absence of 2 mM competitive amino acids inhibitors threonine, 
histidine, phenylalanine or arginine to inhibit hASCT2, System N, B0AT1/system L and ATB0+ 
respectively. The transport was performed in the presence or absence of sodium using buffer 
containing [3H]-glutamine and in the presence or absence of amino acid inhibitors. Data are 
presented as mean ± SEM. The numbers in brackets represents the number of independent 
experiments per condition.  
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RWPE-1 Cells are Receptive to Epidermal Growth Factor (EGF) Stimulation.  
To study the regulation of ASCT2, and validate my model, I determined the sensitivity of RWPE-
1 to EGF. Cells were treated with EGF as described in Materials and Methods. Immunoblot 
analysis (Figure 2.5) shows that RWPE-1 cells possess a phospho-tyrosine pathway which is 
activated in response to EGF. My data show that RWPE-1 cells are responsive to EGF within 10 
min of exposure and this effect is blocked in the presence of the EGF receptor inhibitor AG1478 
(Figure 2.6) confirming the activation is due to EGF. I also confirmed that the EGF-dependent 
activation of the cells leads to the phosphorylation of the EGFR receptor and is inhibited as 
expected by the inhibitor. Data (Figure 2.7), show that phosphorylation of the receptor is correlated 
with EGF exposure in a time dependent manner. Noteworthy is the line showing the status of 
panEGFR in the presence of the inhibitor AG1478; in this context, the EGF receptor undergoes 
dimerization without the consequent activation of the downstream pathway, this causes an 
aggregation of non-functional dimeric receptor which in turn causes the detection of a more intense 
band on the immunoblot (Figure 2.7). 
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Figure 2.5. EGF induces tyrosine phosphorylation of proteins in RWPE-1. RWPE-1 cells were 
grown as described in Materials and Methods and were treated in the presence or absence of EGF. 
The membranes were probed with antibodies against phosphorylated tyrosine protein (P-tyr) and 
-actin. Total lysate of EGF-treated HeLa cells was used as a positive control. Exposure time of 
the film ranged between 1 and 5 min. Densitometry of the immunoblot obtained with ImageJ is 
shown. Representative blot of 2 independent experiments.   
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Figure 2.6. EGF-induced tyrosine phosphorylation of protein in RWPE-1 cells is inhibited 
by AG1478. RWPE-1 cells were grown as described in Materials and Methods and were treated 
in the presence or absence of EGF and in the presence or absence of EGF-R inhibitor AG1478 (20, 
40, and 60 µM). The membranes were probed with antibodies against phosphorylated tyrosine 
protein and -actin. Densitometry of the immunoblot obtained with ImageJ is shown. 
Representative immunoblot of 3 showing similar results.  
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Figure 2.7. EGF receptor is tyrosine phosphorylated by extracellular EGF in RWPE-1 cells.  
RWPE-1 cells were treated in the presence or absence of EGF (300 ng/mL, 3, 5, and 10 min), and 
in the presence or absence of EGFR inhibitor (AG1478, 10 min, 20 µM). Cell were collected, and 
the extracted protein prepared for immunoblotting as described in Materials and Methods. 
Membranes were probed with antibodies against phosphorylated EGFR (P-EGFR), total EGFR 
(Pan-EGFR), and -actin. Densitometry of the immunoblot obtained with ImageJ is shown. 
Representative immunoblot of 3.  
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EGF Increases ASCT2-dependent Glutamine Uptake in RWPE-1 With No Effect on Protein 
Abundance.  
Based on previous findings (Ribeiro et al., 2007, Lee et al., 2010, Jones et al., 2012), I 
hypothesized that activation of the EGFR-stimulated signalling pathway would lead to the 
regulation of glutamine uptake in RWPE-1. To confirm this proposed model of ASCT2 regulation, 
I treated the cells with EGF and measured [3H]-glutamine uptake. My data confirm that EGF 
stimulation increases the overall uptake of glutamine in RWPE-1 by 23 % (Figure 2.8). 
Based on the observations that ASCT2 is very abundant in RWPE-1 and it makes a 
significant contribution to the overall glutamine transport in RWPE-1 cells, I hypothesized that 
ASCT2-dependent uptake will be regulated by EGF leading to an EGF-stimulated increase in 
glutamine transport. To confirm this, I conducted functional assays in the presence or absence of 
EGF while targeting only the ASCT2-dependent [3H]-glutamine uptake. My data confirm that 
EGF-stimulation leads to a more than doubling of the ASCT2-dependent glutamine uptake (Figure 
2.9).  
EGF-stimulated increases in ASCT2-dependent uptake could be due to several 
mechanisms including, but not limited to: increases in ASCT2 protein abundance, increases in 
transporter activity, downregulation of protein turn-over, trafficking and so on. Given the short 
time frame of regulation (3 min), I hypothesized that increases in ASCT2 protein expression were 
not likely to be involved in the observed increase in glutamine uptake. I confirmed that, following 
EGF treatment, there was no change in ASCT2 relative mRNA expression (Figure 2.10 a) or 
overall protein levels in RWPE-1 (Figure 2.10b).  
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Figure 2.8. Total sodium-dependent [3H]-glutamine uptake increases in the presence of EGF.  
RWPE-1 cells were kept in sodium buffer (5 h, 37 °C). Sodium dependent [3H]-glutamine transport 
was measured in the presence or absence of EGF. and is expressed as picomoles of substrate per 
mg of protein at 3 min (pmols/mg/3min). Each value represents the mean ± SEM (n= 5). (*) 
p<0.05.  
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Figure 2.9. ASCT2-dependent [3H]-glutamine uptake increases 3-fold after EGF treatment.  
RWPE-1 cells were grown and treated as described in Materials and Methods. hASCT2-dependent 
uptake was selected by inhibiting the other transporters present in RWPE-1 with 2 mM arginine, 
histidine, phenylalanine, and 20 µM nimesulide to inhibit ATB0+, system N, system L, and B0AT1 
respectively. The ASCT2-dependrnt [3H]-glutamine transport was measured in the presence or 
absence of EGF and expressed in picomoles per milligrams of protein at 3 min (picomoles/mg 
protein/3min).  Each value represents the mean ± SEM (n= 3). (***) p<0.001.
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Figure 2.10. Effects of extracellular EGF on ASCT2 expression and protein levels in RWPE-
1 cells.  (A) EGF does not affect hASCT2 mRNA expression. RWPE-1 cells were grown as 
described in Materials and Methods and kept in sodium buffer (5 h, 37 °C). ASCT2 mRNA 
expression levels in the presence or absence of EGF (30 min, 37 °C) is shown. Each value 
represents the mean ± SEM (n= 5). P>0.05. (B) EGF does not affect ASCT2 protein levels in 
RWPE-1. Membranes were probed with antibodies against hASCT2 (Millipore) and β-actin. 
Representative immunoblot (n= 4). 
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The EGF Stimulated Increase in ASCT2-dependent Glutamine Uptake in RWPE-1 is Due to 
an Increase of Transporter Presence at the Plasma Membrane.  
Following confirmation that ASCT2 is responsible for the EGF-stimulated increase in glutamine 
uptake and that this is not due to rise in ASCT2 protein levels, I hypothesized that the underlying 
mechanism of regulation was likely to be regulated trafficking and/or oligomerization of the 
transporter at the membrane. Conformational changes of ASCT2 due to either de/phosphorylation 
of interacting proteins or of the transporter itself could also lead to regulated changes in function 
(Ribeiro et al., 2007, Lee et al., 2010, Angonno, 2012). I found that EGF-stimulated increase in 
ASCT2-dependent glutamine uptake is due to an increase in ASCT2 at the cell membrane. 
Biotinylation assays confirmed that EGF-stimulation leads to an increase (30 %) in ASCT2 at the 
plasma membrane compared to the untreated biotinylated control (Figure 2.11). Detection of 
cytosolic phosphorylated EGF receptor and biotinylated total EGF receptor before and after the 
treatment are also shown. This control is essential in showing the EGF-dependent activation of the 
receptor. When EGF binds to the receptor, a self-phosphorylation event occurs and the receptor 
gets internalized (Tomas et al., 2014). Furthermore, analysis of untreated RWPE-1 cells via 
fluorescence confocal microscopy confirmed that approximately 60 % of the fluorescently labelled 
endogenous ASCT2 is localized within the bi-layer (Figure 2.12a), as expected for a membrane 
transporter, while the remaining protein appears to be distributed either underneath the plasma 
membrane or intracellularly (possibly undergoing post-translational processing).  
Analysis of EGF treated RWPE-1 cells via fluorescence confocal microscopy suggested a 
change in the distribution of ASCT2, such that 70 - 80 % of endogenous ASCT2 was re-distributed 
to the plasma membrane (Figure 2.12b). RWPE-1 cells stained with secondary antibody only were 
used as a negative control to show the absence of non-specific binding and artefacts (Figure 2.12c). 
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Since confocal microscopy provides somewhat qualitative data, I confirmed these 
observations using a quantitative approach; in-plate flow cytometry assays data suggest a 25 % 
increase in ASCT2 presence at the plasma membrane stimulated by EGF (Figure 2.13).  
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Figure 2.11. EGF induces an increase of ASCT2 protein at the plasma membrane in RWPE-
1 cells. RWPE-1 cells were grown and treated in the presence or absence of EGF in as described 
in Materials and Methods. In the figure, immunoprecipitated surface ASCT2 is represented by a 
band (75 kDa) which increases in intensity in the presence of the EGF treatment Equal loading of 
sample protein was ensured by using the same concentration of Sulfo-NHS-SS-Biotin (1 mg/mL) 
in all samples and by incubating an equal amount of cell lysate (500 µg) with streptavidin-
conjugated beads (60 µL) during the purification step (IP). Densitometry of surface biotinylated 
hASCT2 obtained with ImageJ software, is shown. Data is presented as mean ± SEM (n= 3). 
P<0.05. Raw data is also shown   
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Figure 2.12. EGF induces an increase of surface ASCT2 transporter at the plasma 
membrane.  RWPE-1 cells were treated as described in Materials and Methods. In the absence of 
the treatment (A) ASCT2 (red) is distributed at the plasma membrane in small clusters with a 
yellow/orange signal (white arrows). Most of the signal seems to be distributed just underneath 
the bilayer (yellow arrows), with punctate signal around the nuclei. In the presence of external 
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EGF (B) an increase in ASCT2 at the plasma membrane (yellow/orange signal) can be detected, 
while the punctate signal around the cytoplasm decreases. Nuclei (blue) were stained with DAPI 
and cells membrane (green) were stained with WGA Alexa488. Scale bar – 10 µm. Images (A) 
and (B) 1 to 3, are Z stacks collected at 0.25 µm intervals (26 slices) with a Zeiss laser scanning 
confocal fluorescent microscope at 64X. Control cells (C) probed with secondary antibodies and 
membrane stain only are shown. Images are representative of 3 independent experiments. 
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Figure 2.13. EGF induces an increase of ASCT2-related fluorescence at the plasma 
membrane. RWPE-1 cells were treated as described in Materials and Methods Analysis of the 
surface fluorescence emitted by labelled hASCT2 was performed using Acuity Meta express 6 
software and it shows a 25 % increase in surface fluorescence in the presence of EGF when 
compared to untreated cells. Statistical analysis was performed with Graph Pad Prism and data 
represent the mean ± SEM (N= 5). p<0.05 (*).  
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Discussion 
In the last decade, numerous studies have highlighted the importance of the ASCT2 transporter in 
the development and proliferation of tumours (Oka et al., 2012). In prostate adenocarcinoma, a 
correlation between the expression of ASCT2 with the aggravated form of the disease has been 
revealed (Li et al., 2003). In another study, a correlation between the inhibited activity of the 
transporter and the reduced ability of the prostate tumour cells to grow and develop has been 
reported (Wang et al., 2015). However, our current understanding of the biology of human ASCT2 
is very limited, in particular, the physiological role and mechanisms of regulation of the transporter 
are yet to be elucidated in a non-disease context. Hence, the objective of this study was to identify 
and characterize a cell model that can be used as a tool in enhancing my understanding of the 
biological function and regulation of endogenous human ASCT2, in a physiologically relevant 
environment  
I propose that RWPE-1 cells are a suitable model for the study of hASCT2 transporter and 
a novel tool in the context of investigating the expression and functionality of glutamine 
transporters in the prostate. The expression of the endogenous canonical isoform of the human 
ASCT2 transporter (SLC1A5) that I identified in RWPE-1 cells, correlates with previous studies 
where it is widely distributed and overexpressed (Bungard and McGivan, 2005, Li et al., 2003, 
Wang et al., 2015).  
The endogenous ASCT2 protein detected in RWPE-1 is consistent with that described in 
studies conducted with yeast overexpressed and purified human ASCT2 (Pingitore et al., 2013, 
Scalise et al., 2014) and with that described in studies concerning the glycosylation of 
heterologously expressed hASCT2 in HEK-293 cells (Console et al., 2015, Marin et al., 2003). 
Furthermore, in my study I show the first evidence of the distribution of the endogenous hASCT2 
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protein in RWPE-1 which is very similar to that observed in 3T3Ll cells and in several breast 
cancer derived cell lines as it has the same punctate pattern mostly concentrated at the plasma 
membrane and around the endoplasmic reticulum (van Geldermalsen et al., 2015, Takahashi et al., 
2015). My functional studies have confirmed that hASCT2 is the major contributor to the uptake 
of glutamine in RWPE-1. This reflects earlier results in the literature, using similar techniques, in 
which ASCT2 was also found to be the major contributor of glutamine uptake in C2 cells (Avissar 
et al., 2008), human hepatocytes, and liver-derived cells (Bode et al., 1995, Bode, 2001). Along 
with having shown the first evidence of amino acid transport in RWPE-1 by ASCT2, I was also 
able to detect the individual contribution to the transport of both B0AT1 and ATB0+ which has 
not been described before. Other transporters involved in maintaining the glutamine homeostasis 
within RWPE-1 were identified in systems N and L; however, I had no means to distinguish 
between the individual members of these two families (Avissar et al., 2008). Nevertheless, on the 
basis of the information available in various tissue-specific gene expression databases, I came to 
the conclusion that the most probable contributors may be SNAT1 and SNAT2 (system N) and, 
LAT1 and LAT2 (system L). I have not detected any contribution from system A. 
Studies conducted in vivo have shown a correlation between exposure to growth hormones 
and amino acids uptake (Iannoli et al., 1997, Ray et al., 2003). Some studies have also correlated 
ASCT2 transporters’ activity with EGF suggesting that this transporter may be essentially involved 
in the cellular metabolic processes beyond the disease context (Avissar et al., 2008, Palmada et 
al., 2005, Wang et al., 2015, Rosario et al., 2013). Therefore, I have investigated the effects of 
EGF on the regulation of the transporter in RWPE-1 cells. I have confirmed that EGF stimulates 
ASCT2-dependent glutamine uptake confirming previous studies (Avissar et al., 2008, Palmada 
et al., 2005). I found a discrepancy between the small increase in total glutamine uptake (23%) 
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induced by EGF and the noticeable tripling of the ASCT2-dependent glutamine uptake in the 
presence of EGF. This could be due to the fact that, in a non-manipulated environment, the 
presence of EGF may induce an upregulation of some transporters’ activity and a downregulation 
of others. On the other hand, when all other transporters but ASCT2 are inhibited, this causes an 
even more dramatic preference toward ASCT2, in response to the sudden need for glutamine 
stimulated by EGF.  
Nevertheless, we confirmed the EGF-dependent stimulation of the ASCT2-dependent 
uptake acts via regulated trafficking of the transporter to the plasma membrane as reported for 
other transporters and receptors (Jorissen et al., 2003, Jones et al., 2012). In conclusion, I have 
shown that RWPE-1 cells are an excellent research tool in which to undertake further studies of 
the biology and the regulation of endogenous hASCT2. Furthermore, I have shown that ASCT2-
dependent glutamine uptake and cellular distribution can be regulated by EGF.  
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Chapter 3 : Interactors and regulators of ASCT2  
 
Introduction 
Human ASCT2, a member of the solute carrier 1 (SLC1) family, is a Na+-dependent neutral amino 
acid exchanger widely distributed in many organs. The ubiquitous presence of ASCT2 highlights 
the important physiological role of this transporter (Kanai and Hediger, 2003, Kanai and Hediger, 
2004, Albers et al., 2012, Oppedisano et al., 2007, Oppedisano et al., 2010, Utsunomiya-Tate et 
al., 1996). Moreover, ASCT2 expression is frequently upregulated in human cancers, and silencing 
of ASCT2 results in mechanistic target of rapamycin (mTOR) downregulation, a decrease in 
glutamine uptake, and subsequent cell death, which suggests a possible role in the maintenance of 
the cancer phenotype (Bungard and McGivan, 2004, Bungard and McGivan, 2005, Fuchs et al., 
2007, Gegelashvili et al., 2006, Wang et al., 2014). Studies on the substrate interaction site of 
ASCT2 have led to the development of more effective competitive inhibitors such as H-ser(Bzl)-
OH (BenSer) (Grewer and Grabsch, 2004) and l-γ-glutamyl-ρ-nitroanilide (GPNA) (Esslinger et 
al., 2005) which have permitted more targeted pharmacological studies of ASCT2 and more 
specific analysis of the effects that the inhibition of ASCT2-dependent uptake has on cell 
metabolism (Wang et al., 2015, Marshall et al., 2017). Studies conducted in primary human 
trophoblasts have shown that mTOR is involved in the regulation of transporters by modulation of 
their trafficking and amino acid uptake (Rosario et al., 2013). Studies in Xenopus laevis oocytes 
suggest a direct link between the glutamine uptake by hASCT2 and signalling to or via mTOR (Li 
et al., 2003, Nicklin et al., 2009). Similarly, a study conducted in colon adenocarcinoma cells (C2 
and Caco-2), found a correlation between EGF signalling and the regulation of ASCT2/B0AT1-
B0AT2 which may be regulated in an mTOR dependent manner (Avissar et al., 2008). Despite 
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these findings, my knowledge of the underlying components and mechanisms of regulation of 
ASCT2 are still unclear, particularly in a non-pathological environment.  
Transporters and receptors can be regulated by several different mechanisms including 
phosphorylation events and interaction with accessory proteins (Ribeiro et al., 2007, Lee et al., 
2010, Anggono and Huganir, 2012, Jones et al., 2012). Interestingly, an interaction between 
ASCT2 and the scaffold protein PDZK1 has been recently described (Scalise et al., 2014). PDZK1 
is involved in the formation of multi-protein complexes, which are involved in the coordination 
and regulation of several solute carriers such as OCTN1 (Kato et al., 2005), OCTN2, and PEPT1 
(Sugiura et al., 2008), resulting in changes of transport’s activity  and regulated recycling and/or 
trafficking, often in response to growth factors (Ghosh et al., 2000, Hu et al., 2009, Kim et al., 
2013, Walther et al., 2015). Therefore, I hypothesized that PDZK1 may also be involved in the 
regulation of hASCT2 with a similar complex formation mechanism. 
 Furthermore, to fully understand the regulation of ASCT2, it is necessary to identify 
putative protein-protein interactions (PPI) beyond PDZK1. For example, screenings for the EGF 
receptor via tandem mass spectrometry studies (Lu et al., 2016) and for the serotonin transporter 
SERT via affinity purification (AP) and mass spectrometry (MS) studies (Seyer et al., 2016) have 
identified a physical interaction with ASCT2, although the physiological relevance is unclear. 
Nevertheless, identifying members of the interactome of ASCT2 could help explain factors and 
mechanisms involved in the transporter regulation. To investigate this, I performed a large-scale 
membrane two hybrid (MYTH) screening which has been previously successful in the 
identification of relevant interactors for other membrane proteins such as ABC transporters and 
ENTs (Snider et al., 2013, Stasi et al., 2014, Thaminy et al., 2003, Yao et al., 2017, Petschnigg et 
al., 2017).   
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Materials and Methods 
 
Materials 
Keratinocyte serum free medium (K-SFM- 17005042), Dulbecco’s modified Eagle’s medium 
(DMEM), bovine pituitary extract (BPE), fetal bovine serum (FBS), supplemental epidermal 
growth factor (EGF), and Hank’s balanced salt solution (HBSS) were purchased from Life 
Technologies (Burlington, ON). Fluorescently labelled secondary antibodies, plasma membrane 
and nuclear dyes were purchased from Invitrogen (Carlsbad, CA). Goat HRP-conjugated anti-
rabbit antibodies were purchased from BioRad (Mississauga, ON). Primary antibodies against β-
actin (#4970), RICTOR (#9476), SGK1 (#12103), 4E-BP1 (#9644) and phospho-4E-BP1(#9459), 
S6K1 (#2708) and phospho-S6K1 (#9206), Akt (#8596) and phospho-Akt (#4060) were purchased 
from Cell Signalling Technologies (Danvers, MA). The chemiluminescent substrate for 
immunoblot analysis was purchased from Mandel Scientific (Guelph, ON). Labelled glutamine 
([3H]-glutamine) was purchased from Moravek Biochemicals (Brea, CA). and the amino acids 
used in this study were purchased from Sigma Aldrich (Oakville, ON). GPNA inhibitor for ASCT2 
was purchased from Sigma Aldrich (#G1135-1G). Antibodies against phospho-RICTOR (#07-
1331) were purchased from Millipore (Billerica, MA). Human ASCT2.rbd-antibody-conjugated 
was purchased from Metafora Biosystems (Evry cedex, France). Primary antibodies against human 
PDZK1 (ab121230) and Phospho-SGK1 (ab55281) were purchased from Abcam Inc. (Cambridge, 
MA). mTOR inhibitors Torin 1 was purchased from Millipore (Billerica, MA) and Xl388 was 
purchased from Santa Cruz Biotechnology (Dallas, TX). All other chemicals were purchased from 
BioShop (Burlington, ON) unless otherwise specified.   
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Cell Culture 
Immortalized human prostate epithelial RWPE-1 cells were purchased from ATCC (CRL-11609) 
and cultured per ATCC’s guidelines. RWPE-1 monolayers are kept in proliferative conditions in 
keratinocyte basal medium supplemented with 0.05 mg/mL of bovine pituitary extract and 5 
ng/mL of human recombinant epidermal growth factor at a temperature of 37 ºC in a humidified 
incubator and a 5 % (v/v) CO2 atmosphere.  
GPNA Treatments 
RWPE-1 cells were cultured as previously described, incubated in sodium uptake buffer (5 h, 37 
°C) and exposed to extracellular GPNA (L-glutamic Acid γ-(ρ-Nitroanilide) (400 µM, 10 and 30 
min, 37 °C). Cells treated thus were either used for functionality assays or lysed for protein kinase 
analysis via immunoblotting.  
Torin 1 and XL388 Treatments 
Cells were grown as described above and kept in Na+-uptake for 5 hr, treated (15 min, 37 °C) with 
either Torin1 (100 nM) or XL388 (700 nM) and in the presence or absence of EGF (300 ng/µL, 3 
min, 37 °C). Cells treated thus were either lysed for protein kinases analysis via immunoblotting 
or used to perform transport functionality assays.  
Protein Extraction and Western Blot Analysis 
RWPE-1 monolayers were grown as described above, washed twice with PBS (4°C), and protein 
extraction was performed using NP-40 lysis buffer. Cell lysates were incubated on ice for 5 min, 
syringed with a 26-Gauge needle to solubilize the plasma membrane and then centrifuged (19000 
g, 5 min, 4 °C). Protein quantification of the supernatant was done using Bio-Rad PC DC Protein 
Assay kit based on modified Lowry assay. The absorbance was read at 750 nm and sample 
concentration was calculated using a standard curve of increasing concentrations of BSA. RWPE-
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1 total cell lysate (10, 20 or 100 µg) containing endogenous protein kinases was resolved by SDS-
PAGE (Bio Rad Mini -PROTEAN Tetra System). The proteins were transferred to a nitrocellulose 
membrane (Bio Rad - 1620090 - 0.45 microns) and activated in transfer buffer. The transfer was 
performed by using a Bio-Rad semi-dry apparatus (20 V, 60 min). The membranes were blocked 
(5 % (w/v) milk/TBST, 1 h, 25 °C) and incubated overnight at 4°C with antibodies against 
RICTOR (1:2000), phospho-RICTOR (1:500), Akt and phospho-Akt (1:3000), SGK1 (1:3000), 
phospho-SGK1 (1:500), S6K1 (1:3000), phospho-S6K1 (1:1000), 4E-BP1 (1:50000), and phospho 
4E-BP1 (1:10000) in 1 % (w/v) milk/TBST. The following day, membranes were washed 3 times 
for 10 min each in TBST, then incubated with goat-anti-rabbit horseradish peroxide conjugated 
secondary antibody (1:3000, 1 % (w/v) milk/ TBST, 1 h, 25 °C). The membranes were then washed 
(3 times for 10 min each in TBST) and incubated in chemiluminescent substrate solution for 1 
minute.  
Densitometry and Normalization 
Densitometry of the bands detected via Immunoblot was obtained using Image J. The 
Normalization was obtained using either β-actin or for phosphorylated kinases, their equivalent 
pan. Relative normalizing value was obtained by dividing all the normalizing controls values (NC) 
by the highest NC density value. The data was normalized by subtracting the densities of my 
protein of interest (PI) and that of the relative normalizing control (rNC) in their respective lanes. 
The untreated control is set at 1 and all treatments are calculated accordingly.  
ASCT2-dependent [3H]-glutamine Transport Assays in the Presence of GPNA. 
Inhibition of ASCT2-dependent glutamine uptake in RWPE-1 cells was measured in the presence 
or absence of the inhibitor GPNA (400 µM, 10 and 30 min, 37 °C). RWPE-1 monolayers were 
plated at ~5 x 104 cells/well in 24-wells culture plates and allowed to adhere for 24 h. Cells were 
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rinsed and kept in sodium buffer for 5 h. Total [3H]-glutamine uptake was measured in the presence 
and absence of sodium. ASCT2-dependent glutamine transport only was measured by pre-treating 
the cells with 2 mM of competitive amino acids inhibitors histidine to inhibit system N, arginine 
to inhibit ATB0+, and 20 µM of competitive inhibitor Nimesulide to inhibit B0AT1 for 15 min at 
37 °C, then cells were immediately exposed to GPNA. Sodium-independent was also measured 
and subtracted by the total glutamine uptake to obtain the Na+-dependent fraction and eliminate 
the system L-dependent glutamine transport. Radio-labelled glutamine transport (50 µM [3H]-
glutamine, 2 μCi/mL, 3 min, 25 °C) was measured via the modified cluster-tray method (Gazzola 
et al., 1981) in uptake buffer at 3 min. Transport assays were performed at 37 °C. Following 
transport assays, cells were lysed (4 °C, 1h, shaking) with 2 N NaOH. Protein concentrations of 
cell lysates were determined with a modified protein Lowry Assay (BioRad; Mississauga, ON) 
and [3H]-glutamine uptake was measured by standard liquid scintillation counting. Transport was 
expressed as picomoles of substrate per mg of protein at 3 minutes (pmols/mg/3 min). 
Total and ASCT2-dependent [3H]-glutamine Transport in the Presence of mTOR Inhibitors 
Total and ASCT2-dependent glutamine uptake was measured in the presence of the mTOR 
inhibitors Torin1 and XL388. RWPE-1 monolayers were plated at ~5 x 104 cells/well in 24-wells 
culture plates and allowed to adhere for 24 h. Cells were rinsed and kept in sodium buffer as 
previously described. Total [3H]-glutamine transport was measured in the presence and absence of 
sodium. ASCT2-dependent glutamine transport only was measured as described in Materials and 
Methods and in the presence or absence of either extracellular Torin 1 (100 nM, 30 min, 37 °C) or 
XL388 (700 nM, 30 min, 37 °C). Radio-labelled glutamine transport (50 µM [3H]-glutamine, 2 
µCi/mL; 37 °C) was measured via the modified cluster-tray method in sodium uptake buffer at 3 
min. Following transport assays, cells were lysed (4 °C, 1 h, shaking) with 2N NaOH. Protein 
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concentrations of cell lysates were determined with a modified protein Lowry Assay (BioRad; 
Mississauga, ON) and [3H]-glutamine uptake was measured by standard liquid scintillation 
counting. Transport was expressed as picomoles of substrate per mg of protein (pmols/mg/3 min). 
Immunofluorescence of Endogenous PDZK1 and hASCT2 
To determine the intracellular distribution of endogenous PDZK1, RWPE-1 cells were cultured as 
a monolayer in Keratinocyte complete medium to 65 % confluence on microscopy cover slips (1.5 
µm thickness- Carl Zeiss) and then kept in serum-free media for 15 h. All further steps were 
performed at 25°C unless otherwise specified. Cells were rinsed 3 times with warm (37 °C) HBSS 
and fixed in 2 % (v/v) PFA/HBSS for 20 min. To reduce auto fluorescence, the cells were 
incubated in 50mM NH4Cl in PBS for 10 min then they were washed once with 100mM glycine 
and three times with PBS. Cells were permeabilized for 5 min with 0.1 % (v/v) TritonX-100 in 
PBS (supplemented with 3 % (w/v) BSA), blocked with 10 % (w/v) BSA for 1h and then probed 
with antibodies against PDZK1 (1:500, 3 % (w/v) BSA/PBS, 1 h, 25 °C). Cells were washed three 
times with PBS and probed with AlexaFluor488 donkey anti-rabbit IgG (H+L) secondary 
antibodies (1:2000, 3 % (w/v) BSA/PBS, 1 h, 37 °C). Nuclei were stained with DAPI (1:30000, 
5min), cells were rinsed three times with PBS and were mounted on microscopy slides (0.5 mm 
thickness - Carl Zeiss) with DAKO mounting media and left to dry in the dark overnight. 
To confirm the co-distribution of endogenous ASCT2 and PDZK1, cells were cultured and 
treated as described above; cells were then probed with antibodies against hASCT2.rbd (1:100, 5 
% (w/v) BSA/PBS, 30 min, 37 °C), washed three times and probed with AlexaFluor555 goat anti-
mouse (H+L) secondary antibodies (1:2000, 3 % (w/v) BSA/PBS, 1 h, 25 °C). Afterward, cells 
were probed with antibodies against PDZK1, washed, the nuclei were stained and mounted as 
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described above. All samples were then scanned and analysed using a Zeiss scanning confocal 
fluorescence microscope.  
Generation of HA-ASCT2 Construct  
Plasmid DNA for human HA tagged ASCT2 was purchased from DNA 2.0 (Newark, CA) and 
received in a generic Pj201 vector in a dry form. The gene was designed with unique restriction 
sites at each end of the gene with no alteration of the protein sequence:  a HindIII restriction site 
was placed before the Pj201-HA-hASCT2 start codon, and a KpnI restriction site was placed just 
after the stop codon, following the last 10 amino acids of the HA-ASCT2 C-terminus. A short HA 
tag (YPYDVPDYASLGGP) positioned on the protein putative extracellular loop between the 3rd 
and 4th transmembrane domains. The clone (2 µg) was extracted from the filter paper disk in 50µL 
of RNAse free water via 2 centrifugations at 19000g, 5 min each at 25 °C. Both pj201-HA-
hASCT2 clone and pCDNA3.1 vector, were transformed into DH5α competent cells (Invitrogen, 
Carlsbad, CA) according to the manufacturer’s guidelines. The Gel Extraction Kit (Qiagen Inc., 
Canada), was used to isolate and purify HindIII/KpnI digested fragments from both the 
pCDNA3.1vector (Clontech Laboratories Inc., Mississauga, Canada) and pj201-HA-
hASCT2insert. Purified fragments, HA-hASCT2 insert and pCDNA3.1 vector, were then ligated 
using T4 DNA ligase (New England BioLabs; Pickering, Canada). Ligation reactions were 
incubated for 2 h at 37 °C and then transformed into DH5α competent cells (Invitrogen, Carlsbad, 
CA). Aliquots of 50 and 100 µL were plated on LB-agar supplemented with 50 µg/mL kanamycin 
and allowed to grow for 15 h at 37 °C. Single colonies were selected and grown in LB medium 
supplemented with kanamycin for 8h (8000 rpm) at 37 °C. Clone pCDNA3.1-HA-hASCT2, was 
isolated from bacterial cultures via Genelute Plasmid Mini Prep Kit (Sigma-Aldrich, Oakville, 
Canada); plasmid DNA was either linearized or double digested with restriction enzymes HindIII-
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HF and KpnI-HF (New England BioLabs; Pickering, ON, Canada) and analyzed on a 1 % (w/v) 
agarose gel to confirm a successful ligation. Positive clones were then sequenced in both forward 
and reverse directions at The Centre for Applied Genomics (Peter Gilgan Centre for Research and 
Learning, The Hospital for Sick Children, Toronto, Canada) and those showing correct and in-
frame sequence were further amplified and purified using NucleoBond Xtra Midi EF (Macherey-
Nagel GmbH & Co.KG, Germany). Sequencing primers are shown in Table 3.1. 
 
Table 3.1. Sequencing Primers used in this study. hASCT2 (SLC1A5) primers were designed 
using the Clone manager 9 software and analyzed again via the IDT- Oligo design and analysis 
tool. The remaining primer sequences were provided by The Centre for Applied Genomics (The 
Hospital for Sick Children, Toronto, Canada).  
 
  
hASCT2 sequencing primers - 5'-3' 
Forward TAT CAA GCT TAT GGT GGC CGA TCC TCC TCG AGA C 
Reverse CGT GGT ACC CAT GAC TGA TTC CTT CTC AGA GG 
Int-Forward GGT CTC CTG GAT CAT GTG 
Int-Reverse CTA CCA AGC CCA GGA TGT TC 
pCDNA3.1 vector sequencing primers - 5'-3' 
pCDNA3.1_T7 TAA TAC GAC TCA CTA TAG GG 
pCDNA3.1_BGHR TAG AAG GCA CAG TCG AGG 
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RWPE-1 Transfection for Immunoprecipitation 
RWPE-1 cells were seeded in 60mm plates, allowed to attach for 24 h and reach a density of 85 
% in Keratinocyte complete medium as previously described. Cells were transiently transfected 
with plasmid HA-tagged human ASCT2 using X-tremeGENE HP DNA transfection reagent 
(Roche Diagnostics, cat#06366244001) according to the manufacturer’s protocol. Transfection 
with GFP empty vector was used as a positive control to monitor the transfection efficiency using 
a fluorescence microscope. The transfection reagent and Keratinocyte serum free medium were 
warmed at 25°C. HA-ASCT2 plasmid DNA (5 μg) and 15 µl of X-tremeGENE reagent (1:3 ratio) 
were added to 500 µl medium in an Eppendorf tube with gentle pipetting. The transfection mix 
was incubated for 30 min at 25°C. In this time, the medium of the cells was changed to 5 mL fresh 
complete medium. At the end of the incubation time the transfection mix was added to the plates 
dropwise. The medium was changed 24h later with fresh complete medium and 15h later the cells 
were used for immunoprecipitation.  
Immunoprecipitation of HA Tagged ASCT2  
RWPE-1 cells transiently transfected with pCDNA3.1-HA-hASCT2 vector were washed with PBS 
(4°C) and lysed in NP-40 buffer. For immunoprecipitation, 500 µg protein of the total lysate (in a 
final volume of 200 µl) was incubated with 20µl of anti-HA agarose beads (HA-Tag IP/Co-IP 
Application Set, Thermo Scientific cat#26180Y) for 2 h at 25°C in a spin column with gentle end-
over-end mixing. At the end of the incubation time, the flow through samples were collected by 
pulse centrifuge for 10 sec and the beads were washed 3 times with 0.5 ml of TBST. Immuno-
purified HA-hASCT2 proteins bound to the beads were eluted in 25 µl of 2 X Non-Reducing 
Sample Buffer at 95°C for 5 min and resolved by SDS-PAGE. 
 
77 
 
MYTH Screening for hASCT2  
Membrane yeast two-hybrid (MYTH) screening assays were performed as previously described 
(Snider et al., 2010, Snider et al., 2013, Fetchko and Stagljar, 2004, Lam et al., 2015, Stagljar et 
al., 1998). The membrane yeast two-hybrid (MYTH) system is based on the concept of split 
ubiquitin developed by (Johnsson and Varshavsky, 1994). Human ASCT2 was cloned into MYTH 
vectors pB102 (N-STE2-hASCT2-Cub-LexA-VP16-C) and pB101 (N-LexA-VP16-Cub-
hASCT2-C) which allow for the bait protein (hASCT2) to be fused to the N-terminal and C-
terminal region of the split-ubiquitin (Cub) transcription factors, respectively. These constructs 
were then used to perform the screening against the available Human Prostate Adenocarcinoma 
and the Human Adult Colon (NubG-x) commercial libraries. Bait cloning and validation, bait 
transformation into undisclosed yeast strains with all controls (negative and positive) and vectors 
self-activation checks, library screening, and results delivery of the positive prey proteins were 
performed by Hybrigenics Services SAS (Paris, France). 
Statistical analysis  
Data are reported as mean ± SEM, unless otherwise specified. Statistical analysis on the data was 
performed by paired two tailed t-test with Graph Pad Prism 6 statistical software package. 
Differences were considered significant at P <0.05 and P<0.001 with a confidence interval of 99% 
(as indicated). Each value represents the mean of at least triplicate experiments with measures at 
least 6 replicate measurements per condition, unless otherwise indicated. 
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Results 
 
GPNA Inhibition of ASCT2-dependent Glutamine Uptake Effects on mTORC2 
Phosphorylation. 
Previous studies have shown that ASCT2 silencing leads to a downregulation of mTOR followed 
by cell apoptosis within 48h (Avissar et al., 2008, Fuchs et al., 2007). Therefore, I hypothesized 
that pharmacological inhibition of ASCT2 would affect the phosphorylation of the canonical read-
outs of the mTOR downstream pathway. I first confirmed that GPNA (Wang et al., 2015) inhibits 
ASCT2 uptake in RWPE-1 cells, by measuring ASCT2-dependent glutamine transport in the 
presence or absence of the inhibitor. I confirmed that GPNA inhibits ASCT2-dependent glutamine 
uptake by ~70 % (Figure 3.1).  
ASCT2 inhibition and silencing leads to a downregulation of mTOR and eventually 
to cell death (Avissar et al. 2008). mTORC2 is involved in the regulation of Rho dependent 
protein-trafficking to the plasma membrane (García-Martínez and Alessi, 2008, Gulhati et 
al., 2011, Avissar et al., 2008). Therefore, I hypothesized that the pharmacological 
inhibition of ASCT2-dependent transport would result in a decrease in intracellular 
glutamine and this would result in an increase of mTORC2 activity. I found that following 
prolonged inhibition of the ASCT2-dependent transport, mTORC2 activity decreases (
 
Figure 3.2). Within one hour, Rictor phosphorylation increases while p-Akt and p-SGK1 
are unchanged. At the same time, the activity of 4E-BP1 decreases due to its hyper-
phosphorylation, while the activity of p70 S6K1 increases due to its hyper-phosphorylation. The 
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less understood S6K1 isoform, p85, shows a decrease in phosphorylation which may highlight an 
unknown regulation by this kinase.  
 
Figure 3.1. ASCT2-dependent glutamine uptake is inhibited by GPNA in RWPE-1 cells.  
RWPE-1 cells were grown as described in Materials and Methods, treated in the presence or 
absence of competitive amino acid inhibitors and in the presence or absence of GPNA. and 
transport is expressed as picomoles of substrate per mg of protein at 3 min (pmols/mg/3min). Three 
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independent experiments are presented (each condition was conducted in six replicates) Data are 
presented as the average ± SD. (***) p<0.001.  
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Figure 3.2. Pharmacological inhibition of hASCT2-dependent glutamine uptake regulates 
the mTOR pathway in RWPE-1.  RWPE-1 cells were grown as described in Materials and 
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Methods in the presence or absence of GPNA. The membranes were probed with antibodies 
against pan and phosphorylated kinases Representative data of 3 independent experiments is 
shown. Densitometry obtained with ImageJ is shown. Data is shown as average ±SEM. P>0.05.   
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Total and ASCT2-dependent Glutamine Transport is Not Affected by the Inhibition of 
mTOR  
I found that mTORC2 activity is decreased following prolonged inhibition of ASCT2 while the 
activity of mTORC1 seems to increase. Because of cross-talk between the two mTOR pathways, 
it is very difficult to draw conclusions regarding the involvement of either complex in the 
regulation of ASCT2. Therefore, I investigated the effects of mTOR inhibition on the total and 
ASCT2-dependent glutamine transport in RWPE-1 using widely used mTOR inhibitors such as 
Torin1 and XL388 (Liu et al., 2009, Liu et al., 2010, Takeuchi et al., 2013, Thoreen et al., 2009). 
I confirmed that, in the presence of Xl388, both Akt and 4EBP1 are inhibited (hypo-
phosphorylated) even in the presence of EGF therefore confirming the inhibition of both mTORC1 
and mTORC2 complex (Figure 3.3). On the other hand, the inhibition of mTOR by Torin 1 resulted 
in a slightly different outcome: Akt is hypo-phosphorylated and therefore downregulated even in 
the presence of EGF but 4EBP1 seems to be hyper phosphorylated in the presence of Torin, 
suggesting that mTORC1 is not being successfully inhibited (Figure 3.3). I hypothesized that 
inhibition of mTOR, would result in an overall decrease in glutamine uptake due to a decrease of 
ASCT2 availability at the plasma membrane. However, my data show that in RWPE-1, the 
inhibition of mTOR by either XL388 and of mTORC2 by Torin1, had no e effect on either the 
total glutamine transport (Figure 3.4a) or the ASCT2-dependent glutamine uptake (Figure 3.4b). 
Taken together, these data suggest that mTOR may not be involved in the regulation of ASCT2. 
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Figure 3.3 XL388 and Torin1 inhibit mTOR pathway in RWPE-1 cells.  Cells were grown as 
described in Materials and Methods and treated with either Torin1 or XL388 and in the presence 
or absence of EGF. The membranes were probed with antibodies against pAkt, p4E-BP1, β-actin. 
Representative data of 2 independent experiments. 
 
  
85 
 
 
Figure 3.4. Glutamine transport is not affected by the inhibition of mTOR in RWPE-1.  
RWPE-1 cells were grown as described in Materials and Methods. A) Total glutamine transport. 
[3H]-glutamine uptake measured in the presence or absence of Torin1 and XL388is shown. B) 
ASCT2-dependent glutamine transport. ASCT2-dependent [3H]-glutamine uptake measured in 
the presence or absence of the inhibitors (2 mM His and Arg, and Nimesulide) and in the presence 
or absence of Torin1 or XL388 is shown. Data are presented as picomoles of substrate per mg of 
protein (pmols/mg). Each value represents the mean ± SD (n= 1 experiment; n= 6 technical 
replicates per condition). 
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Analysis of Endogenous PDZK1 Confirms Expression and Localization Patterns in RWPE-
1 cells. 
I hypothesized that regulation of ASCT2 in response to EGF may be due to an interacting protein 
or a complex of proteins involved in short-term trafficking which may be regulated via mTOR. 
Therefore, I investigated the possible role of PDZK1, a scaffold protein involved in regulating the 
surface expression of plasma membrane proteins by coordinating their regulatory components in 
epithelial cells (Silver, 2002, D'Amico et al., 2010, Zheng et al., 2014). PDZK1 was previously 
found to interact with ASCT2 (Scalise et al., 2014). I confirmed the presence of PDZK1 protein 
in RWPE-1 cells (Figure 3.5a); which is consistent with previous findings (Luo et al., 2017, Scalise 
et al., 2014, Sugiura et al., 2008, Walther et al., 2015). 
Having confirmed the presence of the PDZK1, I looked at the intracellular localization of 
PDZK1 and determined that PDZK1 is mainly distributed within the cytoplasm of the cells in a 
punctate manner (Figure 3.5b). This pattern is slightly different from the one shown in previous 
studies conducted in transiently transfected cells, where protein abundance may affect protein 
distribution (Choi et al., 2011, Kim et al., 2012). 
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Figure 3.5. RWPE-1 express PDZK1.  (A) PDZK1 protein is present in RWPE-1. RWPE-1 
cells were prepared as described in Materials and Methods. Membrane was probed with antibodies 
against PDZK1. T47D whole cell lysate (ab14899 ABCAM) was used as a positive control. A 
band (75 kDa) representing endogenous PDZK1 detected in all samples is clearly visible. (B) 
Distribution of PDZK1 protein in RWPE-1 cells. RWPE-1 cells were handled as described in 
Material and Methods. Cells were probed with antibodies against PDZK1and fluorescent 
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secondary antibody Alexa Fluor® 488 goat anti-rabbit IgG. Nuclei (blue) were stained with DAPI. 
PDZK1(green) is widely distributed within the cytoplasm in a punctate manner. Scale bar – 10 
µm. Images were collected with a Zeiss laser scanning confocal fluorescent microscope at 64X 
and they are representative data from 3 independent experiments. RWPE-1 cells probed with 
secondary antibody only are shown.  
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ASCT2 and PDZK1 do not Co-immunoprecipitate nor Co-localize in RWPE-1 cells.  
A recent study by Scalise and colleagues (2014) revealed an interaction between ASCT2 and 
PDZK leading us to speculate that PDZK1 could have a role in the EGF-dependent ASCT2 
trafficking.  
To investigate this, I first determined whether co-immunoprecipitation of ASCT2 and 
PDZK1 occurs in RWPE-1 and HEK-293 cells. However, I could not confirm the existence of an 
interaction between the two proteins in either cell model as indicated by Co-IP (Figure 3.6). 
Moreover, there is no co-localization nor co-occurrence between ASCT2 and PDZK1 in RWPE-
1: each protein seems to be distributed in small red or green clusters independently from one 
another and no signal overlapping can be detected by immunofluorescence (Figure 3.7).  
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Figure 3.6. PDZK1 does not co-immunoprecipitate with hASCT2 in RWPE-1.  HEK-293 and 
RWPE-1 cells were grown and transiently transfected with the HA tagged ASCT2 construct as 
described in Materials and Methods. Membranes were probed with antibodies against (A) hASCT2 
and (B) PDZK1. Samples: TL, Non-transfected RWPE-1 or HEK-293 cells total lysate. TLHA-
ASCT2, HA-ASCT2 transfected RWPE-1 or HEK-293 cells total lysate. IP/TL, IP elution of non-
transfected total lysate. IP/TLHA-ASCT2, IP-elution of HA-ASCT2 protein. Representative 
immunoblot of 3 independent experiments.   
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Figure 3.7. ASCT2 and PDZK1 do not appear to co-localize in RWPE-1.  RWPE-1 cells were 
grown, fixed, and permeabilized described in Materials and Methods. Cells were probed with 
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ASCT2.rbd-conjugated antibodies, PDZK1, and secondary antibodies Alexa Fluor® 555 donkey 
anti-mouse IgG and Alexa Fluor® 488 goat anti-rabbit IgG. Nuclei (blue) were stained with DAPI. 
Both ASCT2 (red) and PDZK1 (green) are distributed in a punctate manner within the cells and 
no overlapping signal (yellow-orange) can be detected, which suggests no co-localization. Images 
are representative data of 5 independent experiments and are Z-stacks taken at 28µm intervals (27 
slices) with a Zeiss laser scanning confocal fluorescent microscope-64X. Scale bar - 10µm. 
Negative control of RWPE-1 cells probed with secondary antibodies only is shown.  
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Bioinformatics Analysis of hASCT2 Potential Interactors 
I confirmed that PDZK1 and ASCT2 do not co-localize or interact in RWPE-1. Therefore, to 
proceed in the understanding of the molecular mechanism regulating ASCT2’s regulation I 
attempted to identify other putative interactors by performing the first large-scale MYTH 
screening targeted at hASCT2. Human ASCT2 was used as a prey in two independent MYTH 
screening in which 60 million interactions were tested, yielding 58 potential interactors which I 
sorted by localization and function, as shown in Table 3.2.  
Table 3.2. MYTH screening summary. 
hASCT2 vs. Human Adult Colon library  
Membrane - associated proteins 7 
ER-Golgi trafficking proteins 8 
Proteins with enzymatic activity 9 
Proteins with transporter function 8 
Proteins with diverse or unknown functions 16 
False positive 2 
 
hASCT2 vs. Human Adenocarcinoma library  
Proteins with diverse or unknown functions 7 
False positive 1 
 
 
Their function and possible involvement in hASCT2 regulation, is described in the following 
tables (3.3 to 3.8). 
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Table 3.3. Plasma membrane hASCT2 putative interactors. 
hASCT2 vs. Human Adult Colon NubG-x library  
Gene Protein Function 
ATP13A1 
Manganese 
transporting 
ATPase  
Involved in the manganese transport homeostasis of the endoplasmic 
reticulum.  
CHP2 
Calcineurin B 
homologous 
protein 2 
It has a Na/H exchange activity. Potential activator of the 
calcineurin/NFAT signalling pathway. Binds to and activates 
SLC9A1/NHE1 receptor. Plays a role in the regulation of cell 
proliferation and tumour growth by increasing the calcium-dependent 
phosphatase activity of PPP3CA. 
ADGRE5 Protein ADGRE5 
CD97/ADGRE5 is a membrane protein of the epidermal growth 
factor- 7 transmembrane family (EGF-TM7) that belongs to adhesion 
G protein-coupled receptors (GPCR). 
ATP6AP2 Renin receptor 
Functions as a renin and pro-renin cellular receptor. May mediate 
renin-dependent cellular responses by activating ERK1 and ERK2. 
MS4A8 
Membrane-
spanning 4 
domains 
subfamily A, 
member 8 
May be involved in signal transduction as a component of a 
multimeric receptor complex 
TMC4 
Transmembrane 
channel-like 
protein 4 
Probable ion channel 
TMC5 
Transmembrane 
channel-like 
protein 5 
Probable ion channel 
TMCO3 
Transmembrane 
and coiled-coil 
domain-
containing 
protein 3 
Probable Na+/H+ antiporter. TMCO3 belongs to the monovalent cation 
protein antiporter 2 (CPA2) transporter family. 
SSTR2 
Somatostatin 
receptor type 2 
It is a G-protein coupled receptor for somatostatin-14 and -28. Inhibits 
cell growth through enhancement of MAPK1 and MAPK2 
phosphorylation and up-regulation of CDKN1B. 
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Table 3.4. ER-Golgi trafficking hASCT2 putative interactors. 
hASCT2 vs. Human Adult Colon NubG-x library 
Gene Protein Function 
BCAP29 
B-cell receptor-
associated protein 
2 (Bap29) 
Involved in ER to Golgi vesicle mediated transport. Forms a 
heterodimer with BCAP31. It assists or regulate BCAP31 
function. 
BCAP31 
B-cell receptor-
associated protein 
31 (Bap31) 
It is a chaperone protein. Plays role in the export of secreted 
proteins from and to the ER. Helps in the recognition of misfolded 
proteins and aids their targeting to the ER associated degradation. 
EMC7 
ER membrane 
protein complex 
subunit 
7 (C15orf24) 
It is member of EMC which is implicated in ER-associated 
degradation, lipid transport and tethering between the ER and 
mitochondrial outer membranes, and assembly of multi-pass ER-
membrane proteins. 
TVP23C 
Golgi apparatus 
membrane protein 
TVP23, homolog 
C (FAM18B2) 
Probably involved in vesicle mediated transport and protein 
secretion 
GPR89A 
Golgi pH regulator 
A 
Works as a voltage dependent anion channel which modulates 
Golgi functions through the regulation of acidification. 
HERPUD1 
Homocysteine 
responsive 
endoplasmic 
reticulum resident 
ubiquitin-like 
domain member 1 
protein 
Component of ER-associated degradation system. Involved in 
ubiquitin-dependent protein degradation. 
SERP1 
Stress associated 
endoplasmic 
reticulum protein 1 
Protects unfolded target proteins against degradation during ER 
stress. SERP1 interacts with the chaperone calnexin, thus 
controlling early biogenesis of membrane protein. 
SSR3 
Translocon-
associated protein 
subunit gamma 
(TRAP-gamma) 
TRAP (signal sequence receptor complex) is required for the 
translocation of secretory and membrane proteins in the 
endoplasmic reticulum. 
 
 
 
 
 
  
96 
 
Table 3.5. Enzyme-related putative hASCT2 interactors. 
hASCT2 vs. Human Adult Colon NubG-x library 
Gene Protein Function 
HMOX2 Heme oxigenase 2 
Catalyze the degradation of heme to carbon monoxide (CO), ferrous 
iron, and biliverdin. It is a defensive mechanism against oxidative 
stress. 
OACT2 
Lysophospholipid 
acyltransferase 5 
(LPCAT3) 
Involved in lipid and phospholipid biosynthesis and metabolism. 
RNF5 
E3 ubiquitin-
protein ligase 
RNF5 
It is involved in protein ubiquitination. Has E2-dependent E3 
ubiquitin-protein ligase activity. 
TMEM195 
Alkylglycerol 
monooxygenase 
(AGMO) 
Glyceryl-ether monooxygenase that cleaves the O-alkyl bond of ether 
lipids. 
SPCS2 
Signal peptidase 
complex subunit 2 
Component of the microsomal signal peptidase complex which 
removes signal peptides from nascent proteins as they are 
translocated into the lumen of the ER. 
TECR 
Very-long-chain 
enoyl-CoA 
reductase 
It is involved in the fatty acid biosynthesis pathway. 
UBIAD1 
UbiA 
prenyltransferase 
domain-containing 
protein 1 
Prenyltransferase that mediates the formation of menaquinone-4 
(MK-4) and coenzyme Q10. 
 ELOVL1 
Elongation of very 
long chain fatty 
acids protein 1 
Catalyzes the first reaction of the long-chain fatty acids elongation 
cycle. Exhibits activity toward saturated C18 to C26 acyl-CoA 
substrates, with the highest activity towards C22:0 acyl-CoA.  
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Table 3.6. Transporter- related putative hASCT2 interactors. 
hASCT2 vs. Human Adult Colon NubG-x library 
Gene Protein Function 
ABCA8 
ATP-binding 
cassette sub-family 
A member 8 
Transporters characterized by their ability to transport lipids across 
cellular membrane and to regulate lipid homeostasis.  
AQP7 Aquaporin 7 
Member of aquaglyceroporins which transport glycerol as well as 
water. Adipocyte glycerol permeation through AQP7 was appointed 
as a novel regulator of adipocyte metabolism and whole-body fat 
mass. 
SLC13A2 
Solute carrier family 
13 member 2 
(NaDC1) 
Low affinity Na+/dicarboxylate transporter. 
SLC23A1 
Solute carrier family 
23 member 1 
(SVCT1) 
Na+-dependent vitamin C transporter. Mediates electrogenic uptake 
of vitamin C. Highly expressed in adult small intestine, kidney, 
thymus, ovary, colon, prostate and liver 
SLC35A3 
UDP-N-
acetylglucosamine 
transporter 
Is the major UDP-N-acetylglucosamine transporter in mammals. It 
forms a heterologous complex with UDP-galactose transporter in the 
Golgi’s membranes. 
 SLC5A1 
Sodium/glucose 
cotransporter 1 
(SGLT1) 
It actively cotransports glucose/ Na+ into cells and is completely 
functional as a monomer. Expressed in the intestine, kidney, heart, 
trachea, and prostate. 
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Table 3.7. hASCT2 putative interactors with unknown or diverse function. 
hASCT2 vs. Human Adult Colon NubG-x library 
Gene Protein Function 
ARL6IP5 
PRA family 
protein 3 (JWA) 
Novel microtubule-associated protein, which regulates cancer 
cells differentiation and chemically inducted apoptosis.  
C18orf32 
UPF0729 protein 
C18orf32 
It has signal transducer activity and it may activate the NF-kappa-
B signalling pathway 
OCIAD1 
OCIA domain 
containing protein 
Endosome. Isoform 1 is highly expressed in many tissues, 
including testis, brain, placenta, ovary, prostate and mammary 
gland. 
CCL2 
C-C motif 
chemokine 2 
- 
ACKR1 
Atypical 
chemokine 
receptor 1, 
(DARC) 
Belongs to the G-protein coupled receptor 1 family. Localization: 
early endosome, recycling endosome, cell membrane. 
ACKR4 
Atypical 
chemokine 
receptor 4 
(CCR11) 
Belongs to the G-protein coupled receptor 1 family. Localization: 
early endosome, recycling endosome, cell membrane. 
FUNDC2 
FUN14 domain-
containing protein 
2 
Mitochondrial outer membrane, nucleus 
 FIS1 
Mitochondrial 
fission 1 protein 
Is involved in the fragmentation of the mitochondrial network and 
its perinuclear clustering. 
TM4SF20 TM4 L6 protein 20 Transmembrane protein 20 
ITGB1 Integrin beta-1 Belongs to the integrin beta chain family 
TMEM128 
GRB2, (Growth 
factor receptor-
bound protein 2) 
Adapter protein that provides a critical link between cell surface 
growth factor receptors and the Ras signalling pathway. 
TMEM19/ TM protein 19 Transmembrane protein 19 
TMEM237 TM protein 237 Component of the transition zone in primary cilia.  
TMEM242 TM protein 242 Transmembrane protein 242 
TMX2 
Thioredoxin-
related TM protein 
2 
Involved in cell redox homeostasis. 
TMEM35B TM protein 35B Transmembrane protein 35B 
  
99 
 
 
Table 3.8. Putative hASCT2 interactors with miscellaneous function identified in the 
Human Prostate Adenocarcinoma library. 
Gene Protein Function 
C14orf1 
Probable 
ergosterol 
biosynthetic 
protein 28 
Endoplasmic reticulum multi-pass membrane protein. 
CNIH4 
Protein cornichon 
homolog 4 
Involved in G protein-coupled receptors (GPCRs) trafficking from 
the ER to the cell surface; it promotes the exit of GPCRs from the 
early secretory pathway, likely through interaction with the COPII 
machinery. 
EBP 
3-beta-
hydroxysteroid-
Delta (8), Delta 
(7) -isomerase 
It is involved in the pathway cholesterol biosynthesis, which is part 
of the steroid biosynthesis. ER multi-pass membrane protein. 
Nucleus envelope, Cytoplasmic vesicle.  
EMC4 
ER membrane 
protein complex 
subunit 4 
May mediate anti-apoptotic activity. 
SERP1 
Stress-associated 
endoplasmic 
reticulum protein 
1 
Interacts with target proteins during their translocation into the 
lumen of the ER. Protects unfolded target proteins against 
degradation during ER stress. May facilitate N-glyc of proteins after 
termination of ER stress.  
TMCO3 
TM and coiled-
coil domain-
containing protein 
3 
Probable Na+/H+ antiporter. 
TMEM14A 
TM protein 14A 
(PTD011) 
Inhibits N-(4-hydroxyphenyl) retinamide-induced apoptosis through 
the stabilization of mitochondrial membrane potential 
HDAC6 
Histone 
deacetylase 6, 
nucleus 
Common false positive.  
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Discussion 
I previously confirmed that EGF stimulates an increase in glutamine uptake mainly due to an 
increase of hASCT2 protein at the plasma membrane which is consistent with the regulation 
described for other transporters (Lee et al., 2010, Ribeiro et al., 2007, Jones et al., 2012). The 
underlying mechanism of regulation of redistribution of ASCT2 appears to involve mTOR; 
however, it is not known whether the signal is transmitted via mTORC1 or mTORC2 pathway 
(Shimizu et al., 2014, Takahashi et al., 2015). Here I evaluated the downstream effects of short-
term pharmacological inhibition of ASCT2-dependent uptake on the downstream targets of both 
mTOR complexes.  
The serine/threonine kinase mTOR is conserved across all eukaryotes and its key role 
within cells is an amino acid sensor and regulator of cell metabolism (Malik et al., 2013, 
Shimobayashi and Hall, 2014). The mTOR complex 1 mTORC1, is regulated by amino acids, 
oxidative stress, insulin and growth factor signalling (Hay and Sonenberg, 2004). These stimuli 
promote cell growth and proliferation by controlling the activity of protein S6K1 and the 
eukaryotic initiator factor 4E-BP1, which in turn increases protein synthesis, regulating 
mitochondrial metabolism and autophagy (Gingras et al., 1999, Kim and Guan, 2015, Ruvinsky 
and Meyuhas, 2006, Wang and Proud, 2006, Klionsky, 2010). In contrast, mTORC2 is strictly 
controlled by growth factors and, via its downstream targets which are SGK1 protein, PKC and 
Akt kinases, it is thought to coordinate cytoskeleton assembly, cell size, and sodium transport 
(Alessi et al., 2009, Fingar and Inoki, 2012, Oh and Jacinto, 2011).  
My data show that in RWPE-1 cells, inhibition of ASCT2 using GPNA (Esslinger et al., 
2005) leads to a decrease in activity of mTORC2 due to hyper-phosphorylation of the complex 
protein RICTOR and an increase in activity of mTORC1 determined via detection of the hyper-
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phosphorylation of S6K1 p70; this is unexpected since previous findings have shown that long 
term inhibition and/or silencing of ASCT2, in certain cancers where its expression is very 
abundant, leads to a downregulation of mTORC1 activity (Bruhat et al., 1997, Wang et al., 2014, 
Wang et al., 2015). Also, studies on ASCT2 silencing have shown that the absence of ASCT2 
results in decreased amino acid uptake, mTOR downregulation, and finally cell death (Fuchs and 
Bode, 2005, Fuchs et al., 2007, Kudo and Boyd, 2002). 
The activation of mTORC1 results in the hyper-phosphorylation and downregulation of 
4E-BP1 and in the hyperphosphorylation and activation of p70 S6K1 (Shimobayashi and Hall, 
2014). As expected, I found that p70 S6K1 and 4E-BP1 are both hyper-phosphorylated. The 
inhibition of 4E-BP1 due to its hyperphosphorylation is the first step in the activation of the cap-
dependent mRNA translation (Brunn et al., 1997, Gingras et al., 1998, Gingras et al., 1999, Pause 
et al., 1994). This event, effected by the complex FRAP/mTOR at Thr37 and Thr46, serves only 
as a primer for 4E-BP1 which is to be followed by phosphorylation at Ser65 and Thr70, which 
seems to be cell-specific and due to many extracellular inputs (Fadden et al., 1997, Gingras et al., 
1999). Because, as previously described (chapter 2), I did not detect an increase in the expression 
of ASCT2 mRNA following the treatment of RWPE-1 cells with EGF, but only a redistribution of 
the transporter ASCT2 at the plasma membrane, I can conclude that the phosphorylation of 
4EPB1is the first step toward the metabolic readjustment of the cell in response to the decrease in 
glutamine availability. Instead of starting translation of new ASCT2 right away, which may be 
energetically costly, the cells prepare for the possibility of protein translation should the lack of 
amino acids continue. The role of mTOR as a contributor to the regulation of many receptors and 
transporters is well established (Rosario et al., 2013, Almilaji et al., 2012, Roos et al., 2009, 
Shojaiefard et al., 2006). Previous studies have shown that mitogenic stimulation and 
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phosphorylation by mTORC1 leads to activation of ribosomal protein S6 kinase (S6K1) which 
results in negative feedback on mTORC2 by phosphorylating the complex protein RICTOR and 
therefore inhibiting the Akt1 downstream signalling (Dibble et al., 2009, Dufner and Thomas, 
1999, Julien et al., 2010, Sun et al., 2016, Holz et al., 2005, Pullen and Thomas, 1997). 
My data show that inhibition of ASCT2, leads to a decrease in mTORC2 activity, which 
could be due to the previously reported S6K1-dependent negative feedback to PI3K which will 
arrest the signalling cascade (Dancey, 2010, Rahman and Haugh, 2017); this is confirmed by the 
detection of the hyper-phosphorylated and therefore hyper-activated p70 S6K1. Nevertheless, I 
also detected hypo-phosphorylated p85 S6K1 isoform. This may suggest a previously unreported 
regulation of the mTORC2-dependent pathway in response to ASCT2 inhibition, which could be 
specific to RWPE-1 cells. The possible regulative role of p85 S6K1 isoform has not been 
investigated, few studies have focused only its subcellular localization and its association with 
enhanced cellular proliferation and metastasis (Ismail et al., 2013, Rosner et al., 2013, Tavares et 
al., 2015, Amaral et al., 2016). Given the lack of information on p85 S6K1, further studies using 
techniques such as silencing and phosphorylation analysis of this kinase and RICTOR, in relation 
to the EGF-dependent activity and regulation of ASCT2, are needed to confirm this novel putative 
regulation. 
Previous data have shown that mTOR is involved in regulating membrane transporters 
(Edinger and Thompson, 2002, Edinger et al., 2003, Edinger, 2007, Liu et al., 2004, Peng et al., 
2002, Peyrollier et al., 2000, Roos et al., 2009, Roos et al., 2007). Specifically, mTORC2 has been 
found to be a crucial regulator of the activity and trafficking of systems A and L in human 
trophoblast cells (Rosario et al., 2013). However, in all these cases the molecular mechanisms of 
this form of regulation are still unclear.  
103 
 
A possible growth factor-dependent regulation of ASCT2 through SGK1 has been 
previously suggested in Xenopus laevis oocytes (Palmada et al., 2005). This led us to presume that 
the EGF-dependent regulation of ASCT2’s activity and trafficking could involve SGK1 and signal 
transduction through mTORC2. I predicted that, if SGK1 was involved in the regulation of 
ASCT2, the inhibition of ASCT2 activity would result in an increase of mTORC2 activity 
following an upregulation SGK1 and mechanisms involving protein trafficking through the early 
endosome pathway. However, in RWPE-1 the inhibition of ASCT2 did not have any consequences 
on the phosphorylation of SGK1 or Akt. This led us to the conclusion that either I was unable to 
detect a very finely tuned regulation or that simply neither SKG1 nor Akt are involved in the short-
term regulation of ASCT2 in these cells. 
To exclude the possibility of a lack of sensitivity in detecting changes in the kinases 
phosphorylation on my part, I inhibited mTOR using pharmacological inhibitors Torin1 and 
XL388 (Takeuchi et al., 2013, Thoreen et al., 2009, Xiong et al., 2017). Data suggest that short 
term inhibition of mTOR activity does not affect the overall glutamine uptake in RWPE-1 cells or 
downregulate the ASCT2-dependent glutamine transport. This is in contrast to previously 
published data showing a reduction of mTOR activity due to silencing of ASCT2 (Avissar et al., 
2008) and reduction of ASCT2 functionality due to mTOR silencing and inhibition with rapamycin 
in hepatoma cells (Fuchs et al., 2007). This could be due to the fact that: (a) RWPE-1 cells are not 
as sensitive to the inhibitors as other cell lines are, therefore longer (chronic) treatments are 
required to induce a detectable regulation of the transporter by mTOR; (b)The regulation could  be 
so subtle that is undetectable in non-tumorigenic cell line; (c) The regulation between ASCT2 and 
mTOR previously described in other tumour-derived cell lines, may be a manifestation of a 
dysregulated system which may not occur in a non pathological environment To better understand 
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this mechanism of regulation, further studies are required. A summary of my findings is depicted 
in Figure 3.8. Overall, I don’t have enough information to confirm that a link between ASCT2 
inhibition and mTOR activity exists; this is mostly due to biological variability and to the fact that 
the regulation we are looking for may occur differently in my model, compared to overstimulated 
systems which are dysregulated where any changes are detected promptly and abundantly.  
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Figure 3.8. A cartoon depicting the putative downstream effects of ASCT2 inhibition on 
mTOR pathways.  The inhibition of ASCT2 due to GPNA results in a lack of glutamine uptake 
which causes a decrease in 4E-BP1 activity due to its hyper-phosphorylation on tyrosine 37 and 
46. This phosphorylation primes the kinase which initiates signalling for protein translation and 
stops the regulation of mTORC1 on the downstream pathways involving SGK1 and Akt. At the 
same time, p70 S6K1 is hyper-phosphorylated and activated which may be the cause of the 
detected downregulation of RICTOR, while isoform p85 S6K1 is hypo phosphorylated and its 
activity decreased. Upregulation (green arrow); downregulation (red arrow); no change in activity 
(yellow parallel). Dotted black arrows represent unverified regulation.  
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There was no information on ASCT2 interactome until very recently, when the scaffold 
protein PDZK1 was described as an in vitro interactor of the transporter (Scalise et al., 2014). 
PDZK1 is involved in the regulation of many members of the SLCs family such as OCTN1 (Kato 
et al., 2005), OCTN2, and PEPT1 (Sugiura et al., 2008).Its regulation involves change of transport 
activity rate, regulated recycling and/or trafficking (Kim et al., 2012, Walther et al., 2015). PDZK1 
is expressed exclusively in epithelial cells and it is overexpressed in various carcinomas where it 
interacts with MAP17, a membrane-associated protein involved in regulation of cell proliferation 
(Kocher et al., 1998, Ghosh et al., 2000). In breast cancer, PDZK1 is also part of many complexes 
where it interacts with and coordinates, in response to growth factors such as EGF, the interplay 
of multiple proteins at the cell surface (Hu et al., 2013, Kim et al., 2012, Kim et al., 2013). Hence, 
given the regulatory nature of PDZK1 I presumed this protein may be a potential candidate in 
having a role in the regulation of ASCT2. 
Furthermore, given the rapid response of the transporter to the EGF stimuli, I predicted that 
the mechanism may occur via selective and/or regulated recycling of the transporter residing just 
beneath the membrane, which is recruited through an unknown signalling pathway stimulated by 
EGF, which could include PDZK1.  
I have confirmed the presence and the distribution of PDZK1 in RWPE-1 cells and my data 
are similar to those previously reported (Choi et al., 2011, Scalise et al., 2014, Walther et al., 
2015). Since I could not confirm the interaction between ASCT2 and PDZK1, I decided to look at 
other ASCT2-interacting proteins which could be involved in the EGF-dependent regulation of the 
transporter. I used the membrane yeast two-hybrid system to perform a large-scale screening of 
ASCT2 putative interactions.  
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The membrane yeast two-hybrid (MYTH) system is based on the concept of “split 
ubiquitin” developed by Johnsson and Varshavsky, (1994) which was re-adapted and used as a 
sensor for the detection of protein-protein interactions in S. cerevisiae (Fetchko and Stagljar, 2004, 
Lam et al., 2015, Snider et al., 2010, Snider et al., 2013, Stagljar et al., 1998). 
MYTH is a widely utilized technique to get insight into membrane protein’s interactome, 
however it poses some challenges that may affect the interpretation of the data such as the presence 
of high numbers of false negative/positive interactions due to unnatural aggregation of the 
overexpressed bait and preys, false positive may be due to interactions of the protein in yeast that 
are not typically co-expressed in a mammalian cell; also, some interactions which are typical of 
mammalian systems, may not occur in yeast, therefore overlooking biologically relevant 
interactions which go undetected. Despite its limitations, the MYTH system offers a powerful tool 
for the detection of interactions between membrane-associated proteins and possible regulators in 
vivo. Furthermore, the interaction network I present here is the first ever large output screening 
performed for hASCT2 and is a powerful resource which will help researchers move forward in 
understanding of the regulation of hASCT2. 
I performed a bioinformatic analysis of the results using the STRING database of predicted 
functional association between proteins (Szklarczyk et al., 2015). I found that hASCT2 is 
associated with various proteins involved in a surprisingly diverse variety of functions some of 
which are already part of complexes with specific roles (Figure 3.9). Some of the MYTH-detected 
interactions are unexpected but they may indicate yet undiscovered roles for ASCT2 along with 
unidentified regulatory pathways (Ratushny and Golemis, 2008, Serebriiskii and Golemis, 2001). 
Here, I highlight ASCT2 putative protein interactions which show potential for future studies on 
regulation, along with some interaction which may have physiological relevance.  
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Figure 3.9. Integrated hASCT2 interactome.  Novel interactions identified by MYTH screening 
are represented by the coloured spheres and ASCT2 (SLC1A5) is used as a central node. The links 
shown represent interactions of various nature previously reported in the BioGRID database. 
Known false positive interactions were excluded from this analysis. The interactome was 
generated using STRING software.   
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Among the ASCT2 interactors I detected via MYTH, there are some which possess 
possible biologically relevant and/or regulatory roles such as the UDP-N-acetylglucosamine 
transporter (SLC35A3). SLC35A3 is a membrane protein localized in the Golgi apparatus which 
transports uridine diphosphate-N-acetylglucosamine (UDP-GlcNAc) (Ishida et al., 1999). 
SLC35A3 was correlated with the development of autism spectrum disorder, epilepsy and 
arthrogryposis (Edvardson et al., 2013). The gene encoding SLC35A3 is downregulated in patients 
with pancreatic adenocarcinoma along with another putative ASCT2-interacting protein I found in 
my screening, the Golgi apparatus membrane protein TVP23 homolog C (TVP23C) (Liang et al., 
2012) which is involved in vesicle-mediated trafficking (Matsuda et al., 2003).  
My screening also confirmed an interaction of ASCT2 with the Ring Finger Protein 5 
(RNF5) which has been previously described in breast cancer (Jeon et al., 2015). Upon paclitaxel-
induced ER stress in BCa cells, RNF5 associates with ASCT2 and SNAT2 (SLC38A2), facilitating 
the ubiquitination and degradation of these two transporters. This reduces glutamine uptake, 
decreases TCA cycle components levels and mTOR signalling while promoting cell death (Jeon 
et al., 2015). Moreover, RNF5 receives a signal from the ER stress-associated response complex, 
two of which proteins were also found as putative interactors of ASCT2 in my MYTH screening: 
the translocon-associated signal receptor gamma (SSR3) and the stress associated ER protein 1 
(SERP1).  
The interaction between ASCT2 and members of the ER-stress associated complex could 
have a correlation with the alleged protective action carried out by ASCT2 on brain cells under 
ischemic conditions (Gegelashvili et al., 2006); it seems that at low pH, ASCT2 acts as a scavenger 
for the protonated glutamate (glt+), thereby reducing the toxic activity of this neurotransmitter in 
the brain. 
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One very interesting putative interactor of ASCT2 found in my MYTH screening is the calcineurin 
B homologous protein 2 (CHP2). This protein is required for the localization and stabilization of 
the Na+/H+ exchanger (SLC9A1/NHE1) at the plasma membrane (Pang et al., 2001, Pang et al., 
2004) and in the regulation of transporters in breast cancer (Amith and Fliegel, 2013). 
CHP2 shares 63% sequence similarity and 32% sequence identity with Calcineurin B 
(CnB) (Figure 3.10), the regulatory subunit of calcineurin, and it can interact with the catalytic 
subunit of calcineurin (CnA) as CnB would (Li et al., 2008).  
 
 
Figure 3.10. Sequence alignment between calcineurin B and CHP2.  Calcineurin B and CHP2 
share 32% sequence identity and two of the four calcium binding sites necessary for its 
activation (blue). The alignment was performed using CLUSTALO.  
 
Calcineurin is a Ca2+/calmodulin-dependent serine/threonine protein phosphatase which 
takes part in many cellular processes including calcium-dependent signal transduction pathways 
involving calmodulin (Rusnak and Mertz, 2000, Shibasaki et al., 2002, Aramburu et al., 2004, Li 
et al., 2011). This could be of interest due to data showing the interaction between ASCT2 and the 
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serotonin transporter (SERT) in HEK-293 (Seyer et al., 2016). It seems that the co-expression of 
these two proteins in HEK-293 cells affects the glycosylation and cell-surface localization of 
SERT causing a decrease in serotonin uptake, while depletion of ASCT2 via RNAi causes an 
increase in serotonin uptake in primary mesencephalon neurons. SERT activity and trafficking are 
finely modulated by a complex network of kinases and phosphatases including the 
Ca2+/calmodulin-dependent phosphatase calcineurin (Seimandi et al., 2013). Several studies have 
shown how phosphorylation can regulate membrane proteins by inducing conformational changes 
and altering protein-protein interactions, activity and trafficking (Mohapatra et al., 2007). As 
previously described, CHP2 can bind to the catalytic subunit of calcineurin (CnA) and being so 
similar to its homologue (CnB), it could potentially use the same docking consensus sequence of 
calcineurin B, to bind target protein which is represented by the conserved motif LxVP, usually 
localized on the C-terminus of target proteins (Li et al., 2011). Therefore, I conducted in silico 
bioinformatic analysis of the ASCT2 sequence to detect putative binding sites for calcineurin B 
and I confirmed the presence of the putative binding site, as predicted, is located intracellularly on 
the C-terminus of hASCT2 at residues 510-513 (Figure 3.11). 
 
 
 
Figure 3.11. Putative calcineurin B docking region on hASCT2.  I detected the motif (LxVP) 
located at the C-terminus of human ASCT2 (Q15758) sequence at residues 510-513.  
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The presence of the putative docking site in the sequence of hASCT2 suggest that, similar 
regulatory processes involving de-phosphorylation of ASCT2 by calcineurin are plausible and they 
could open a new and very exciting line of research which was unknown until now.  
I went further in my analysis and I considered the possibility of an interaction between 
ASCT2, calcineurin, and calmodulin. As previously elucidated, calcineurin is dependent on 
calcium ions and calmodulin to be fully activated (Li et al., 2011) and calmodulin has been 
previously described as a modulator of the equilibrative nucleoside transporters (ENTs) (Bicket et 
al., 2016). Therefore, I conducted in silico analysis of the human (Q15758), mouse (P51912), and 
rabbit (019105) ASCT2 protein sequences using the Calmodulin Target Database (Yap et al., 
2000). I detected one high probability putative binding region represented by the motif 
CxxxxLxxxL, located intracellularly at the N-terminus between residues 41 and 62, conserved 
among all three homologs of ASCT2 (Figure 3.12).  
 
 
 
Figure 3.12. Putative calmodulin binding site on ASCT2.  I analyzed the human (Q15758), 
mouse (P51912), and rabbit (019105) ASCT2 protein sequences using the Calmodulin Target 
Database (Yap et al. 2000). One high probability putative binding site (black bar) was found, 
located at the N-terminus of ASCT2, between residues 41 and 62. The bioinformatic software 
examines the sequence and scores the motifs on potential binding to large hydrophobic residues 
such as Phe, Val, Ile, Leu, or Cys (Rhoads and Friedberg, 1997).  
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As previously described, ASCT2 and the EGFR receptor physically interact and they are 
co-regulated (Lu et al., 2016). In my MYTH screening for hASCT2 I found proteins which are 
related to EGFR such as the transmembrane and coiled-coil domain-containing protein 3 
(TMCO3), a member of the monovalent cation protein antiporter 2 transporter family, which is 
considered a putative Na+/H+ antiporter. A previous MYTH screening for EGFR revealed TMCO3 
as a yet unconfirmed interactor of the receptor (Deribe et al., 2009).  
Another putative interactor of ASCT2 is the growth factor receptor-bound protein 2 
(GRB2), which is an adapter protein which acts as a link between receptors located at the plasma 
membrane and Ras signalling pathway associated with EGFR .This isoform inhibits the EGF-
induced transactivation of the RAS-responsive element by suppressing proliferative signals, and 
triggers programmed cell death (Lowenstein et al., 1992, Dharmawardana et al., 2006, Giubellino 
et al., 2008, Belov and Mohammadi, 2012, Ahmed et al., 2013). 
The Adhesion G Protein-Coupled Receptor E5 (ADGRE5) was also detected as a putative 
ASCT2 interactor. ADGRE5 is a mediator of cell-cell interactions and its expression is increased 
by the epidermal growth factor (EGF), this leads the progression and invasion of thyroid carcinoma 
cells (Hölting et al., 1995, Steinert et al., 2002, Ward et al., 2013). These interactions, if confirmed 
with biochemical and functional assays, may be potential targets for future investigation of the 
regulation of ASCT2. 
Other interesting ASCT2 interactors found in my MYTH screening include: the renin 
receptor (ATP6AP2) (Nguyen, 2010), the somatostatin receptor type 2 (SSTR2) (Grant et al., 
2004, Grant et al., 2008), and the Na+/dicarboxylate cotransporter 1 (SLC13A2) (Pajor, 1996, 
Okamoto et al., 2007).  
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Given what has been reported to date about ASCT2, it is natural to assume that it is likely 
to be a very versatile protein, which transcends its role as mere amino acid transporter, used widely 
in different tissues as co-regulator of transporters and receptors.   
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Chapter 4 : Overview and General Considerations 
 
The canonical isoform of human Alanine Serine Cysteine Transporter 2 (hASCT2) plays an 
important role in the physiology of many tissues by providing the cells with neutral amino acids 
(Bröer et al., 1999, Gegelashvili et al., 2006, Torres-Zamorano et al., 1998) and acting as an 
anchoring “receptor” for human retroviruses (Antony et al., 2011, Marin et al., 2003). In the last 
decade, the interest toward this transporter has changed and many studies focused on the 
importance of the ASCT2 in the so called “Warburg effect” (Vander Heiden et al., 2009, Liberti 
and Locasale, 2016b). An increasing number of published investigations have highlighted ASCT2 
as one of the most important glutamine transporters involved in the support of the shift toward 
anaerobic metabolic pathways by cancerous cells, to meet the consequent need for more glutamine 
to support the generation of ATP thereby maintaining the cancer phenotype (Fuchs et al., 2007, 
Kanai and Hediger, 2004, Palmada et al., 2005, Wang et al., 2013, Wang et al., 2014, Vander 
Heiden et al., 2011). An example of this role can be found in prostate adenocarcinoma, where a 
correlation between the increased expression of ASCT2 is correlated with highly aggressive form 
of the disease (Li et al., 2003). Another example of this role is highlighted by correlation between 
the inhibited activity of the ASCT2 in prostate tumour cells and their consequent reduced ability 
to grow and develop (Wang et al., 2015). Also, some data have been reported on the possible 
regulation of ASCT2 by mTOR and growth factors suggesting that this transporter may be 
essentially involved in the cellular metabolic processes beyond the disease context (Avissar et al., 
2008, Palmada et al., 2005, Rosario et al., 2013).  
While these studies provide some contributions to our knowledge of the regulatory 
mechanisms of ASCT2, our current state of understanding of the biology and the mechanisms of 
regulation of human ASCT2 are still unclear due to contradicting findings and by the fact that most 
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of our data derives either from in vitro models or from disease contexts, where the physiology is 
altered (Palmada et al., 2005, Wang et al., 2015, Avissar et al., 2008, Pingitore et al., 2013, Scalise 
et al., 2014, Rosario et al., 2013). Hence, the main objective of this study was to fill this gap by 
identifying and characterizing a cell model which can be used as a tool in increasing my 
understanding of the biological function of ASCT2 and the proteins contributing to the regulation 
of the endogenous human isoform of the transporter in a physiologically relevant environment.  
I characterized RWPE-1 cells as a physiologically relevant model, suitable for the study of 
endogenous hASCT2. This cell line represents a novel tool in the context of investigating the 
expression and functionality of glutamine transporters in the prostate. My findings on the 
expression, distribution, and functionality of the canonical isoform of the endogenous human 
ASCT2 (SLC1A5) in RWPE-1 cells correlate with previous studies in other cell lines (Bröer et al., 
1999, Bungard and McGivan, 2005, Li et al., 2003, Marin et al., 2003, Pingitore et al., 2013, 
Scalise et al., 2014, Takahashi et al., 2015, van Geldermalsen et al., 2015, Wang et al., 2015). 
Most importantly, my functional studies of endogenously expressed ASCT2 provide the first 
evidence of selective transport by ASCT2 relative to other amino acid transporters in RWPE-1 
cells. I have confirmed that hASCT2 is the major contributor to the uptake of glutamine in RWPE-
1, reflecting earlier results obtained in C2 cells (Avissar et al., 2008), human hepatocytes, and 
liver-derived cells (Bode et al., 1995, Bode, 2001). Of great interest was the identification of the 
individual contribution of B0AT1 and ATB0+ to the glutamine transport, which has not been 
described before and specifically not in RWPE-1 cells. Other transporters involved in maintaining 
the glutamine homeostasis within RWPE-1 cells were identified in systems N and L. Although it 
was not possible to distinguish between the uptake of the individual members of these two families, 
by using information available in various organ-specific gene expression databases, I concluded 
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that the most probable contributors may be SNAT1 and SNAT2 (system N) and LAT1 and LAT2 
(system L). The lack of knowledge on the individual members of these systems limits our 
understanding of the glutamine homeostasis at the molecular level in the body and more in-depth 
are needed to shed light on this matter.  
As described extensively in chapter 2, studies conducted in vivo have shown a correlation 
between exposure to growth hormones and amino acids uptake (Iannoli et al., 1997, Ray et al., 
2003, Ray et al., 2005). My data show that ASCT2-dependent glutamine transport and its cellular 
distribution can be regulated by extracellular EGF, with no effects on overall protein level within 
the cell, therefore confirming previous studies on ASCT2 regulation (Avissar et al., 2008, Palmada 
et al., 2005). This mode of regulation is similar to the modulation of other transporters and 
receptors by growth factors (Almilaji et al., 2012, Roos et al., 2007, Rosario et al., 2013, Shimizu 
et al., 2014, Takahashi et al., 2015, Lee et al., 2010, Jones et al., 2012, Ribeiro et al., 2007, Jorissen 
et al., 2003). 
The role of mTOR as a contributor to the regulation of many receptors and transporters has 
been previously reported (Shojaiefard et al., 2006, Almilaji et al., 2012, Roos et al., 2009, Rosario 
et al., 2013, Shimizu et al., 2014, Takahashi et al., 2015). Therefore, I hypothesized that the EGF-
dependent regulation of endogenous human ASCT2 regulation might occur via mTOR. My data 
(chapter 3) show that in RWPE-1, the pharmacological inhibition of ASCT2 using GPNA leads to 
a decrease of mTORC2 activity due to hyper-phosphorylation of the complex protein RICTOR 
and to an increase of mTORC1 activity as detected through hyper-phosphorylation of p85 S6K1; 
this finding was unexpected compared with previous findings in which long term inhibition and/or 
silencing of ASCT2 leading to a decrease of mTORC1 activity (Wang et al., 2014, Wang et al., 
2015). Inhibition of mTOR using Torin1 and Xl388, had no effect on the overall glutamine uptake 
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or the ASCT2-dependent glutamine transport in RWPE-1. This is in contrast with previously 
published data showing a reduction of mTOR activity due to silencing of ASCT2 (Avissar et al., 
2008) and reduction of ASCT2 functionality due to mTOR silencing and inhibition with rapamycin 
in hepatoma cells (Fuchs et al., 2007). 
Therefore, I can not confirm nor deny the possible role of mTOR in the regulation of the 
EGF-dependent regulation of ASCT2 and, given the complexity and the cross-talk between the 
two mTOR pathways, further studies are required to better understand this mechanism of 
regulation. Nevertheless, I may have uncovered a previously undescribed regulation of mTORC2 
via the p85 S6K1 isoform in response to ASCT2 inhibition, which could be specific to RWPE-1 
cells and may affect the regulation of the trafficking of ASCT2. p85 S6K1 is an overlooked kinase, 
which was never included amongst the possible targets of mTOR. Few studies have focused on its 
localization and only recent data have associated this isoform overexpression with enhanced 
cellular proliferation (Amaral et al., 2016, Ismail et al., 2013, Rosner et al., 2013, Tavares et al., 
2015).  
 
Limitations 
RWPE-1 cells were chosen for my studies for the characteristics outlined in Chapter 2; however, 
they are not normal, therefore some of the regulatory mechanism involved in cell metabolism may 
be altered although in smaller measure, when compared to totally dysregulated systems, such as 
tumour derived-cell lines. To eliminate this issue, primary cell lines should be used in the future, 
possibly obtained from the same source to guaranty repeatability.  
In determining the mRNA expression of ASCT2, a limiting factor was highlighted by the 
use of housekeeping genes (HKGs). It has been widely reported that even the expression of such 
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genes can be altered in response to many treatments. This was overcome by utilizing three of the 
most stable most stable genes HKGs and normalizing according to Vadesompele and colleagues 
(2004). 
It is important to point out that my Immunofluorescence protocol was not designed to 
highlight the subcellular localization of ASCT2 other than its distribution at the plasma membrane 
and general subcellular localization. To obtain further insight, a combination of standard SDS-
PAGE immunoblotting of cell lysates fractionated over a sucrose gradient to separate the plasma 
membrane fraction from the other membranous fractions within the cell (i.e. hASCT2 present in 
vesicular pools rather than at the membrane) can be used. Also, immunofluorescence with 
appropriate markers (Early endosomes-GFP dye; lysotracker for lysosomes; ER-tacker from the 
endoplasmic reticulum…) should be used to determine the proportion of hASCT2 in different cell 
compartments. 
Although an established technique, immunoblot can be limiting when trying to quantify 
changes in kinase phosphorylation or exact proteins’ molecular weights are needed. In the first 
case, alterative technique could be used in the future to better understand and quantify the changes 
in kinases’ activity in response to changing cellular environment such as in cell kinase assay or 
crisps. For what concerns antibodies specificity, I am convinced that the antibodies used in my 
studies are indeed detecting the correct proteins; however, there is a chance of non-specific binding 
occurring for PDZK1, and this could be why no co-localization between ASCT2 and PDZK1 was 
detected in RWPE-1. This could be overcome completely by utilizing a more quantitative approach 
such as high-resolution mass spectrometry.  
The use of ASCT2.rbd “antibody” for the detection of the protein results in a highly specific 
labelling; however, because the ligand binds to ASCT2 facing extracellularly this poses some 
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technical challenges when utilizing Immunofluorescence. ASCT2 is glycosylated and WGA, 
membrane stain, binds to the available sugar at the plasma membrane therefore masking the 
epitope utilized by the ASCT2.rbd ligand to bind to the transporter. This was overcome by 
labelling for ASCT2 first and then staining the membrane with WGA. However, this caused the 
loss of some of the membrane stain. 
Future work 
This dissertation describes very early stages in the understanding of the regulation of ASCT2. 
Looking forward, to continue this work a more refined and sustained approach to ASCT2 and 
mTOR inhibition in RWPE-1 cells needs to be developed and compared to a highly cancerogenic 
sister cell line such as RWPE-3 cells, to better understand the differences occurring in the 
regulation of ASCT2 and the triggers of the metabolic changes. 
Furthermore, studies on the putative regulation of mTORC2 via p85 S6K1 and of the 
proteins involved in ASCT2’s trafficking (Yang et al., 2017), could be used to identify connections 
between these events and expand our knowledge of the regulation of the transporter (chapter 2).  
Additionally, studies on the phosphorylation of ASCT2 could be extremely beneficial to 
my understanding of the transporter regulation. Some of the most basic regulatory processes are 
undertaken following de/phosphorylation of target sites present on transporters by kinases such as 
PKC and PKA, therefore inducing conformational changes, altering protein-protein interactions, 
activity, sorting and degradation, and trafficking (Mayati et al., 2017, Xu et al., 2017, Grimsrud et 
al., 2010, Mohapatra et al., 2007, Reyes et al., 2011). For example, the in-silico analysis of 
ASCT2’s sequence using both NetPhos 2 and NetPhosK1 prediction servers revealed the presence 
of phospho-sites for PKA, CaMKII, and CKII (Figure 4.1). Of particular interest is the 
phosphorylation site for CaMKII, which is a Ca2+/calmodulin regulated kinase. 
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Figure 4.1. Putative hASCT2 topology showing putative predicted phosphorylation sites. 
hASCT2 putative topology was designed using Protter online tool. (Omasits et al., 2013). 
 
The information obtained from studies of the phosphorylation of ASCT2, will give us a 
more in-depth understanding on how the cells respond to metabolic changes and EGF growth 
signalling via ASCT2 regulation, which may include a contributive regulation via mTOR; this 
could provide interesting potential therapeutic target for cancer and other conditions.  
Another knowledge gap in the study of ASCT2 regulation is represented by the lack of 
information on the ASCT2 interactome. For example, the investigation of the interaction between 
ASCT2 and human calcineurin B homologous protein 2 (CHP2) (chapter 3) and the localization 
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of all the regulatory sites necessary for calmodulin, CHP2 and CamKII to regulate hASCT2 in a 
Ca2+/calmodulin-dependent manner (Figure 4.2) 
 
 
Figure 4.2. Putative hASCT2 topology showing putative docking sites and phosphorylation 
sites. hASCT2 putative topology was designed using Protter online tool. (Omasits et al., 2013). 
 
Interacting proteins are likely to be involved in the regulation of ASCT2, as described for 
other transporters such as ENTs (Bicket et al., 2016) and could open a new and very exciting line 
of research unknown until now for hASCT2.   
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Appendix 
Abbreviations 
 AG1478 – Tyrphostin (EGF-R inhibitor) 
 Alexa Fluor 488 – Donkey Anti-Rabbit IgG (H+L) Antibody 
 Alexa Fluor 555 – Goat Anti-Mouse IgG (H+L) Antibody 
 Alexa Fluor 594 – Donkey Anti-Rabbit IgG (H+L) Antibody 
 ASCT2 – Alanine Serine Cysteine Transporter 2  
 ATCC – American Type Culture Collection 
 BSA – Bovine serum albumin 
 Caco-2 – human Colorectal Adenocarcinoma  
 Ch+ – Choline 
 Co-IP – Co-immunoprecipitation 
 DAPI – 4.6-diamidino-2-phenylindole 
 DMEM – Dulbecco modified Eagle’s medium 
 DoMo – Donkey anti mouse antibody 
 DoRb – Donkey anti Rabbit antibody 
 EAAC1 – Excitatory amino acid carrier 1 
 EBI – European Bioinformatics Institute 
 EGF – Epidermal growth factor 
 EGFR – Epidermal growth factor receptor 
 ENT – Equilibrative nucleoside transporter 
 FBS – fetal bovine serum 
 FLAG tag – FLAG-octapeptide 
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 Gln – glutamine 
 GoRb – Goat anti Rabbit antibody 
 GPNA – L-Glutamic Acid - γ- ρ -Nitroanilide 
 HA tag – Hemagglutinin tag  
 hASCT2 – Human Alanine Serine Cysteine Transporter 2 
 HBSS – Hank’s balanced salt solution 
 HEK-293 – Human embryonic kidney cells 
 HEPG2 – Human hepatocellular carcinoma 
 HMBS – Hydroxymethylbilane synthase 
 HPRT1 – Hypoxanthine phosphoribosyl transferase 1 
 ICC – Immunocytochemistry 
 IF – Immunofluorescence 
 IP – Immunoprecipitation 
 iRNA – RNA interference 
 LAT1 - L-type amino acid transporter 1 
 MAPK – mitogen activated protein-kinase 
 MeAIB – Methil-aminoisoburitic acid 
 MesNa – MercaptoEthane Sulfonate sodium 
 mRNA – Messenger ribo nucleic acid 
 mTOR – Mechanistic target of rapamycin 
 MYTH – Membrane yeast Two Hybrid  
 NP-40 – (Nonident P-40) octylphenoxypolyethoxyethanol 
 O-Benzyl-L-serine – (S)-2-Amino-3-benzyloxypropionic acid 
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 PBS – Phosphate Buffered Saline 
 PDZK1– Na+/H+ exchange regulatory cofactor NHE-RF3 
 PFA – Paraformaldehyde 
 PI3K – Phosphatidyl inositol 3 kinase 
 PKB/Akt – Serine/threonine protein kinase B 
 PM – Plasma membrane 
 qPCR – Quantitative polymerase chain reaction 
 RBD – Retroviral binding domain 
 Rho GTPase –Guanosine triphosphate hydrolase 
 RT-PCR – Reverse transcriptase polymerase chain reaction 
 RWPE-1 – Human epithelial prostate cells 
 SDS-PAGE – Sodium-dodecyl-sulphate polyacrylamide gel electrophoresis 
 SGK1/3 – Serum and glucocorticoid-regulated kinase 1/3 
 SLC1 – Solute carrier 1 
 Sulfo-NHS-SS-biotin – sulfosuccinimidyl-2-(biotinamido) -ethyl-1,3'-dithiopropionate 
 TBST– Tris Buffered Saline, 0.1% Tween 20 
 THLE-3 – Human epithelial liver cells 
 TMD – Trans-membrane domain 
 Torin1–1-[4-[4-(1-Oxopropyl)-1-piperazinyl]-3-(trifluoromethyl) phenyl]-9-(3-quinolinyl)-
benzo[h]-1,6-naphthyridin-2(1H)-one 
 Na3VO4 – Sodium orthovanadate 
 WGA – Wheat germ agglutinin 
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 XL388 – [7-(6-Amino-3-pyridinyl)-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-[3-fluoro-2-
methyl-4-(methylsulfonyl)phenyl]-methanone 
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Solutions and Buffers 
 Plate coating: 0.01 mg/mL fibronectin, 0.03 mg/mL bovine collagen type I, and 0.01 mg/mL 
bovine serum albumin. 
 Sodium Uptake buffer: 145mM NaCl, 5mM glucose, 1mM CaCl2, 1mM MgCl2, 10mM 
HEPES-Tris and, 3mM K2HPO4, pH 7.4. 
 Sodium-free uptake buffer: 145mM choline chloride, 5mM glucose, 1mM CaCl2, 1mM 
MgCl2, 10mM HEPES-Tris and, 3mM K2HPO4, pH 7.4. 
 PBS: NaCl 140mM, KCl 2.7mM, KH2PO4 1.5mM, and Na2HPO4 8.1mM. 
 NP-40 lysis buffer: 50mM Tris-HCl, 150mM NaCl, 1% (v/v) nonident P-40 detergent, 
10mM Na3VO4, and a cocktail of protease and phosphatase inhibitors (Roche) at pH8. 
 Transfer buffer: 25mM Tris, 192mM glycine, 20% (v/v) methanol. 
 10X RT buffer: 200mM Tris-HCL, 500mM KCl, (pH8.4). 
 Kanamycin 1000x: Kanamycin 50 mg/ml in autoclaved ddH20. 
 Luria-Broth (LB) liquid medium: Bacto-tryptone 1% (w/v), yeast extract 0.5% (w/v), 
and NaCl 1% (w/v) (pH 7). Autoclaved. 
 LB-agar medium: Bacto-tryptone 1% (w/v), yeast extract 0.5% (w/v), and NaCl 1% (w/v) 
(pH 7). Agar 1.5% (w/v) added. Autoclaved. 
 Protein Loading Buffer 5X (PLB 5X): Tris-HCl 60 mM (pH 6.8), glycerol 25% (v/v), SDS 
2% (w/v), β-mercaptoethanol 0.05% (v/v), and Bromophenol Blue 0.1% (v/v). 
 Running buffer 10X: Tris-HCl 25mM (pH 8.3), glycine 192mM, and SDS 0.1% (w/v). 
 TBS 1X: 25mM Tris-HCl, 150mM NaCl (pH 7.5). 
 TBST: TBS 1X and Tween-20 0.5% (v/v). 
 
